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NUCLEAR-TARGETED GOLD NANOPARTICLES ENHANCE THE EFFECTS OF
RADIATION THERAPY WITH AND WITHOUT LIPOSOMAL DELIVERY
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Advisory Professor: Sunil Krishnan, M.B.B.S., M.D.

Less that 10% of pancreatic cancer patients are eligible for curative resection, and clinical
trials evaluating chemoradiation in locally advanced patients with unresectable disease have
been largely disappointing. New and creative therapeutic approaches are needed to address the
unment need for treatment options. The objective of this thesis is to advance radiosensitization
of treatment-resistant densely desmoplastic pancreatic cancer using nanoparticles to surmount
biological barriers to effective particle distribution for DNA-targeting.
Clinical translation of radiosensitizing nanoparticles has stalled owing to technical
challenges. Current strategies to use AuNPs for radiosensitization require large quantities of
gold, kilovoltage x-rays, immediate irradiation after intravenous administration, and repetitive
administrations of AuNPs prior to each radiation dose during a course of fractionated
radiotherapy. To overcome these challenges, the next generation of AuNPs should be
engineered with 2 design criteria: compatibility with multiple radiation platforms, and appropriate
in vivo biodistribution for radiation dose enhancement at low gold quantities.
To address this, nuclear-targeted gold nanoparticles (nAuNPs) are developed as
payloads for the thermosensitive liposomes (TSLs). The nAuNP-loaded liposomes are
biocompatible carriers capable of penetrating the biophysical barriers and reach deep inside the
tumor. Non-invasive thermal stimulation then releases the nanoparticle load at the intended of
site of cellular uptake. The nuclear targeting of gold nanoparticles enhances the local effects of
vii

radiation via generation of short-range secondary electrons in the proximity of the DNA in
aggressive cancer clones.

To test nAuNPs as a radiosensitizing payload of the TSLs, a three-phase plan is
presented. Phase I focuses on AuNP cellular distribution, demonstrating signal specific nuclear
localization. Phase II appraises radiosensitizing effects of nAuNPs in vitro. Finally, Phase III
demonstrates in vivo biodistribution and anti-tumor efficacy of the nAuNPS with and without TLSs
in xenograft models of human pancreatic adenocarcinoma. This 3-phase study advances
triggered-release of nuclear-targeted nanoparticles as a radiosensitizing modality for localized
cancer therapy. This work provides a framework for the development of a readily deployable
class solution for radiosensitization in a variety of tumors.
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Chapter I: Background and motivation
1.1 Pancreatic cancer
Natural history and pathology
Pancreatic cancer is a disease that presents both diagnostic and treatment challenges.
It is currently the fourth leading cause of cancer mortality in the US and slated to become the
second by 2030.[1, 2] The first attempted account of pancreatic cancer by Giovanni Battista
Morgagni in 1761 reported lesions in the pancreas that were largely unsubstantiated due to the
lack of histological analysis at that time.[3] Jacob Mendez Da Costa later revised Morgagni’s
original work and recorded several cases, one of which actually reported a microscopic diagnosis
of adenocarcinoma.[4] Several decades later, this was followed by the advent of resection
attempts in the form of pancreaticoduodenectomies which were subsequently popularized as the
Whipple procedure.[5-10] As discussed later, this type of surgery described in the 20th century
still persists as the only potentially curative treatment option for pancreatic cancer in 2019 despite
the advancements in diagnostic and treatment techniques.
Pathologically, pancreatic cancer is described as an adenocarcinoma that develops from
the ductal epithelium of the exocrine portion of the gland. Ductal adenocarcinoma is the most
common neoplasm, accounting for 85% of pancreatic lesions. Although the literature describes
no direct causative factors of pancreatic cancer, the most frequently linked risk factors include
family history, smoking, diabetes mellitus, obesity, chronic pancreatitis and the presence of
cysts.[11] Briefly, pancreatic cancer progresses through precursor lesions characteristically
described as pancreatic intraepithelial neoplasias (PanINs), which cultivate clonal genetic and
epigenetic alterations.(Fig. 1.1) Less frequently, pancreatic cancer can evolve form mucinous
cystic lesions that advance into intraductal papillary mucinous neoplasms (IPMNs).[12]
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Figure 1.1: Pancreatic cancer development. Progression through the stages of pancreatic
intraepithelial neoplasias (PanINs) associated with increasing cellular atypia. PanIN-1
represents minimal atypia progressing to formation of micropapillae. There is loss of cellular
polarity in PanIN-2, and PanIN-3 demonstrates severe nuclear and architectural atypia. Figure
reprinted with permission from publisher. Noe M, Brosens LA. Pathology of Pancreatic Cancer
Precursor Lesions.[13]

Clinical presentation and diagnosis
Symptoms of pancreatic cancer commonly appear later in the course of the disease,
which is evidenced by the difficulty of early detection and limited curative treatment options. The
majority of patients present with tumors in the head of the pancreas which cause common bile
duct compression with increasing tumor size. This results in obstructive jaundice causing patients
to notice pale-colored stools, dark urine, yellowing of the skin and conjunctival icterus. Due to
the decreased production of pancreatic enzymes, patients usually can experience weight loss,
as well as new onset type 2 diabetes mellitus. With more advanced disease, patients can present
with abdominal pain radiating to the back which can be indicative of nerve involvement by the
tumor. Altogether, the physical examination is non-specific for pancreatic cancer but may incite
additional diagnostic tests given patient demographics and previously mentioned risk factors.[14]
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The next step in management usually involves imaging by means of computed
tomography (CT) with a pancreatic protocol. This allows for visualization of the primary tumor
with respect to surrounding organs and blood vessels, as well as any disease metastasis. The
tumor typically appears as a poorly enhancing lesion with low attenuation on CT in comparison
to surrounding tissues. (Fig. 1.2) Additional imaging modalities that may prove useful include
magnetic resonance imaging (MRI) or endoscopic ultrasound (EUS). Once diagnosed using CT,
the treatment team usually proceeds with an EUS with fine needle aspiration (FNA) for cytological
confirmation of tumor diagnosis. Carbohydrate antigen 19-9 (CA 19-9) is the only US Food and
Drug Administration (FDA) approved biomarker for pancreatic cancer and is usually tested for at
diagnosis. CA 19-9 is a sialylated Lewis (a) antigen with a reported sensitivity and specificity of
roughly 80%.[15] Although beneficial for following disease progression and response to
treatment, CA 19-9 is currently not recommended for screening due to its low positive predictive
value.

Figure 1.2: Computed tomography (CT) of pancreatic cancer for diagnosis. Contrast enhanced
axial images in: (A) parenchymal phase showing a low-attenuation mass in the body of the
pancreas and (B) venous phase demonstrating isointense mass relative to surrounding
parenchyma. Figure reprinted with permission from publisher. Yeh R, Steinman J, Luk L,
Kluger MD, Hecht EM. Imaging of pancreatic cancer: what the surgeon wants to know. [16]
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Prognosis and treatment for pancreatic cancer is usually based upon the TNM staging.
This classification system categorizes patients into one of 3 stages: resectable, locally advanced
or metastatic disease (Table 1).[17-19] With CT imaging providing 70-85% accuracy for resection
prediction, a positron emission tomography (PET) scan can be useful to determine suspected
metastatic disease.[20-22] Additionally, a laparoscopy can be performed to examine the
peritoneum and abdomen in some cases of tumor occurrence in the pancreatic body or tail. The
median survival is 17-23 months for patients presenting with resectable disease treated with
adjuvant chemotherapy, 8-14 months for patients presenting with locally advanced pancreatic
cancer, and 4-6 months for patients who present with metastatic disease.[23] Furthermore, some
patients with resectable disease fall into a subcategory of technically resectable status, but carry
a high risk of a margin-positive resection due to the degree of vascular involvement.
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Table 1: Pancreatic cancer staging definitions per the 7th and 8th editions of the TNM system by AJCC/UICC. Table adapted from AJCC
guidelines.
7th
T1
T2
T3

T4

Tumor limited to
pancreas, < 2cm in
greatest dimension
Tumor limited to
pancreas, > 2cm in
greatest dimension
Tumor extends beyond
pancreas, no
involvement of celiac
axis or SMA
Tumor involves celiac
axis or SMA
(unresectable)
No regional lymph node
metastasis
Regional lymph node
metastasis

Stage
T

N

M

T1

N0

M0

T2

N0

T3

N0

8th
Maximum tumor
diameter < 2cm

T

N

M

IA

T1

N0

M0

Maximum tumor
diameter > 2, < 4cm

M0

IB

T2

N0

M0

Maximum tumor
diameter > 4cm

M0

IIA

T3

N0

M0

Tumor involves
celiac axis, CHA or
SMA
N0
T1- N1 M0
IIB
T1-3 N1
M0 No regional LN
3
metastasis
N1
T4
Any M0
III
T4
Any M0 Metastasis in 1-3
N
(Any N
regional lymph
T)
(N2)
nodes
N2
–
Any Any M1
IV
Any Any M1 Metastasis in > 4
T
N
T
N
regional lymph
nodes
M0 No distant metastasis
No distant
metastasis
M1 Distant metastasis
Distant metastasis
*AJCC – American Joint Committee on Cancer; UICC – Union for International Cancer Control; SMA – superior mesenteric artery
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Treatment strategies
Surgery, chemotherapy and radiation are the backbones of pancreatic cancer treatment.
The current standard of care for early-stage disease is surgery and adjuvant therapy. Surgery is
determined by the anatomic location of the tumor with a pancreaticoduodenectomy (Whipple)
performed for lesions confined to the head of the pancreas, and a distal pancreatectomy for
lesions in the body or tail. Although previously investigated for treatment of pancreatic tumors,
total pancreatectomies are generally reserved for patients with large or multilocular tumors due
to the high rate of post-operative complications.[24] Several trials such as GITSG, ESPAC-3,
RTOG 9704 and many more established the survival advantage of adjuvant chemotherapy when
compared to observation.[25-29] These studies looked at chemotherapy regimens consisting of
5-fluorouracil (5-FU) and gemcitabine).
For locally advanced pancreatic cancer (LAPC), however, there are several on-going
trials to establish the best treatment strategy for these patients. Chemoradiation options with
gemcitabine reported down-staging of roughly 30% for patients with LAPC to resectable disease,
allowing for resection and leading to median survival similar to those patients presenting with
resectable disease.[23] Newer chemotherapy regimens such as FOLFIRINOX (combination 5FU, irinotecan and oxaliplatin) and Abraxane (liposomal formulation of paclitaxel) have also
shown improved survival in this patient population.[19] In the metastatic setting, a combination
of the aforementioned chemotherapy regimens with or without erlotinib has also shown promise.
As previously discussed, only a minority of patients, less than 10%, present with disease
amenable to a margin-negative resection, the only potentially curative treatment for pancreatic
cancer. Even with this curative-intent surgery, the 5-year overall survival rate is only 15-25%.[30]
Among patients with locally advanced pancreatic cancer (LAPC) where the tumor has not
metastasized but involves retroperitoneal vascular structures that preclude surgical resection,
roughly 60-70% achieve a short-lived partial response with a progression-free survival range of
4-6 months after chemoradiation therapy (CRT), an even smaller subset (<15%) are adequately
6

down staged for potential resectability.[31, 32] Contrary to the common perception that all
patients with pancreatic cancer succumb to the disease as a result of distant metastasis, recent
evidence reveals that complications from local tumor progression significantly contribute to
disease-related mortality even with standard dose CRT.[33] Consequently, there is a pressing
need for selective enhancement of tumor responses to local therapies; and besides surgery, RT
is the only other form of localized therapy for pancreatic cancer.

7

1.2 Radiation therapy
Radiation physics
Aforementioned, radiation therapy (RT) is one of the cornerstones of cancer therapy, and
one of the only forms of truly localized therapy in pancreatic cancer. The inception of RT followed
Roentgen’s discovery of X-rays in 1895, and Becquerel’s discovery of radioactivity in 1896. Since
then, technological advances in X-ray production have aimed at higher energies, intensities,
different particle types, improved treatment planning and delivery methods, such as intensity
modulated beams. In RT, penetrating radiation is emitted from either radioactive sources, also
known as brachytherapy, or delivery apparatuses such as linear accelerators (LINACs). RT is
sometimes delivered using special accelerators and exotic particles such as protons, neutrons,
π mesons and other heavy ions.[34]
Radiation is categorized into two major classes based on its capacity to ionize matter: nonionizing and ionizing radiation – Fig. 1.3.[35] Apparent by the name, non-ionizing radiation cannot
ionize matter. Ionizing radiation either directly ionizes matter via charged particles such as
electrons, protons, alpha particles and heavy ions, or indirectly ionizes through neutral particles
such as neutrons and photons – X-rays or gamma rays.[34, 36] Through Coulomb interactions,
directly ionizing radiation particles deposit energy through the charged particle to orbital electrons
of atoms in the medium. Indirectly ionizing particles, however, first produce charged particles,
e.g. photons causing release of electron or positrons, which then deposit energy through direct
Coulomb interactions. Both forms of radiation are used for clinical management of malignant
diseases.

8

Figure 1.3: Electromagnetic spectrum. Depiction of non-ionizing (lower frequency/higher
wavelength) and ionizing (lower frequency/higher wavelength) types of radiation. Ionizing RT
are used for imaging and therapy because they carry more energy used to penetrate tissues.
Figure reprinted with permission from publisher. Tonnessen BH, Pounds L. Radiation
physics.[35]

Clinical LINACs typically operate at an energy range from 10 kVp to 50 MV, and the beam
results from deceleration of electrons within metallic targets. The kinetic energy of the electrons
is transformed into mostly heat in the target (~99%), with a lesser fraction emitted as X-ray
photons. These resultant photons are categorized as either bremsstrahlung or characteristic Xrays. Bremsstrahlung X-rays, also known as continuous X-rays, result from Coulomb interactions
between the atomic nuclei of the target material and incident particles. This interaction results in
a deceleration of the incident particle and partial loss of its kinetic energy (KE). This loss of kinetic
energy produces bremsstrahlung photons (radiative loss). The continuous spectrum of these
photons is due to the fact that their energy ranges anywhere from zero to the KE of the incident
particle. Consequently, the bremsstrahlung spectrum produced depends on the thickness of the
target, atomic number (Z) of the target and the energy of the incident photons.[34, 36]
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Similarly, characteristic X-rays are derived from Coulombic interactions or photoelectric
absorption interactions. These interactions, however, occur between orbiting atomic electrons of
the target material and incident particles (in a typical clinical linear accelerator, these are
electrons or photons). In this interaction, an energy difference is produced by the ejection of the
orbital electron from its shell and filling of this vacancy by another electron from a higher energy
level shell or sub-shell. This difference in energy of the two is subsequently emitted from the
atom as a characteristic photon (X-ray), or transferred to another surrounding orbital electron,
which is also ejected in the form of Auger or Coster-Kronig electrons. The photons discharged
through the transitions of electronic shells or sub-shells comprise of discrete energies that are
‘characteristic’ of precise target atoms in which the transitions occur, hence the name
characteristic X-rays.

Radiation biology
Radiobiology denotes the effects of electromagnetic radiation on biological systems
through ionization reactions. These effects depend on the quality and quantity of radiation, as
well as the biological system affected. Moreover, irradiation of biological systems results in a
series of processes previously described as the physical, chemical and biological phases that
vary in time and scale.[37] Radiation energy, usually over 10 eV (electron volts) produces
ionizations which yield effects that range from cell cycle disturbances and mutations, to DNA
damage and cell death. Within cells, radiation interacts with water or DNA to produce direct (DNA
is damaged by radiation) or indirect (damaged perpetrated via free radical produced by radiation)
effects. Since water accounts for roughly 70% of the total cell mass, there is a higher probability
of radiation interacting with water, and less with DNA given the tightly folded double strand
structure in the nucleus. When direct DNA damage occurs, the result is usually reproductive cell
death in which metabolic function remains intact but the cells are incapable of undergoing
mitosis. During indirect damage, the radiation particle has enough energy to cause ejection of an
electron from the orbital shell of a nearby atom such as water or gold. In the case of water, the
10

electron is ejected from the hydrogen atom resulting in dissociation into a hydrogen and hydroxylfree radical. The free radicals formed through radiolysis of water are highly reactive and capable
of causing DNA damage after migration to the nucleus.[37, 38]
Although several measurements pertain to radiation, absorbed dose is the major metric
used in radiobiology to assess the potential for biochemical changes. As radiation traverses an
absorbing medium, it can pass through the material unaffected or deposit energy that produces
interactions along this path. Absorbed dose is the non-stochastic quantity utilized for radiation.
With indirectly ionizing radiation, kinetic energy is first imparted to secondary charged particles
(KERMA – kinetic energy released per unit mass). These particles can then transfer some of
their energy to the medium (as absorbed dose) or lose some in the form of radiative losses (such
as bremsstrahlung, annihilation). Absorbed dose is considered biologically effective and was
previously measured in units called ‘rad’ or radiation absorbed dose. The current SI unit is gray
(Gy).[36, 37] For reference, 1 Gy (100 cGy) is equivalent to absorption of 1 joule of radiation
energy per kilogram of absorbing material, and 1 Gy (100 cGy) is equal to 100 rads.
However, absorbed dose alone is not adequate for defining net biological effectiveness
of varying radiation types. Linear energy transfer (LET) measures the energy imparted to the
medium as the ionizing particle travels through, and is used to quantify effects of varying radiation
modalities on biological systems – Fig. 1.4.[39] Aforementioned, dose is deposited as the ionizing
particle deposits energy along the track, however, distinct forms of radiation yield variable
numbers of ionizations along the particle’s path. From a microdosimetric view, biologic
effectiveness is based on the energy deposition pattern defined density or spacing of ionization
events.[40] Ionization events in close proximity within a given length result in higher energy
deposition and therefore, greater biological effectiveness per unit for the given radiation. This is
measured in keV/µm, and depends on the mass and charge of the particle. Consequently,
heavier particles yield more ionization events per tract in comparison to photons which generate
secondary electrons with negligible mass. For reference, a 250 keV X-ray (photons) has an LET
roughly 2.0 keV/µm, compared to an ɑ-particle with an LET range of 100 – 150 keV/µm. Of note,
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LET can increase with decreasing particle energy radiation because the number of ionizations
increases as the particle slows down.[41]

Figure 1.4: DNA damage schematic. Depending on the quality of RT (LET), DNA damage can
range from single or clustered sties to simple or complex DSBs. Lower LET. Figure reprinted
with permission from publisher. Lomax ME, Folkes LK, O'Neill P. Biological consequences of
radiation-induced DNA damage: relevance to radiotherapy. [39]

Relative biological effectiveness (RBE) denotes the relative amount of damage to
biological tissues by different types of radiation, given a fixed absorbed dose – i.e, amount of
ionizations. Per the International Committee on Radiological Protection (ICRP), ‘[t]he RBE of one
radiation compared with another is the inverse ratio of the absorbed dose producing the same
effect.’ This allows for comparison of different types of radiation with varying LETs producing the
same biologic effect. Notably, LET and RBE are linearly correlated. RBE increases with LET up
to roughly 100 keV/µm, after which RBE decreases due to the ‘over-kill effect’.[37] This endpoint
is generally as radiobiologic cell death in which the cell loses reproductive ability – also known
as a ‘reproductive’; or ‘clonogenic’ death. In this case, the cell remains physically and
metabolically active for a time following exposure to radiation, with some cells even undergoing
a few cycles of mitosis prior to permanent termination of vital functions.
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Historically, the cell death endpoint is determined using an in vitro plating method that
generates cell survival curves. The fraction of surviving colonies is logarithmically plotted against
the corresponding radiation dose. The goal is to utilize radiation to decrease the population of
clonogenic cells, thereby achieving tumor control. The linear-quadratic or ‘alpha-beta’ formula is
used to fit the survival data on the premise that radiation-induced lethal lesions in cells results
from association of sublesions. ɑ represents the rate of cell kill via a single-hit and β denotes the
rate through a two-hit mechanism. Cell survival curves are illustrations of dose-response curves
to assess the response of tissues to RT.
Clinical radiobiology explores the correlation between physical absorbed dose and the
consequential biological response. As such, any benefit adapting the treatment strategy to
improve the effects on tumors must be balanced with the consideration of the effect in normal
tissues. First analyzed by Holthusen in 1936, dose-response curves are generated for
comparison between tumor and normal tissues to generate a therapeutic index.[37, 42] The
therapeutic index is defined as the tumour response given a defined amount of normal tissue
damage. Subsequently, the therapeutic window defines the potential difference between tumour
response and the tolerated dose as a measure surrogate cost-benefit analysis of the treatment.
Radioprotectors and radiosensitizers are compounds that can influence the therapeutic index by
shifting either the normal tissue curve to the right (protector) or the tumour curve to the left
(sensitizer), allowing for implementation of different and potentially more effective treatment
strategies.[43, 44] Nanotechnology can play a role in delivery and enhancement of radiation
therapy.
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1.3 Nanotechnology
Nanomaterials
With an academic shift away from a big picture collective based on anatomy and
physiology to a more molecular viewpoint, the biological sciences can, and have, benefited
immensely from the advantages of nanotechnology. The integration of nanoscale principles with
biological systems has driven the advancement of expertise to empower biomedical research.
Studies on biological mechanisms, pathways and processes are conducted at the nanoscale
level with physical and chemical techniques enabling improved imaging and control of the
properties of atoms, proteins, and larger molecular structures such as the cell membrane.
Nanoscience involves the study of structures of nanoscale (1-100nm) in at least one
physical dimension, while nanotechnology encompasses real world application of these
structures. Physicist Richard Feyman first discussed the concepts of nanomaterials in 1959 with
his talk ‘There’s Plenty of Room at the Bottom,’ and the term ‘nanotechnology’ was coined over
a decade later by Professor Norio Taniguchi.[45, 46] Compared to molecules and atoms,
nanomaterials are substantially larger in size, which allows for distinctive behavior and
properties. These features are often superior to those of bulk materials because most atoms on
nano-sized objects are on or near the surface resulting in weaker bonds and more reactive
properties.
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Figure 1.5: Size comparison of nanoparticles. Schematic of scale of some common
nanomaterials relative to a water molecule, organic compounds (virus), cells, hair follicle ad
normal household items.

The two major factors contributing are surface effects and quantum effects which are
favorable for dense loading of ligands to these structures.[47] The enhanced surface phenomena
result from the high surface area to volume ratio due to the size of nanomaterials. Furthermore,
the quantum effects or discontinuity in behavior is caused by the confined delocalization of
electrons on the surface of the nanomaterials also imparted by the small size of these particles.
Together, these features allow for physiochemical properties unique to these particles, such as
surface functionalization of various moieties in order to bestow features permitting multiple
purposes simultaneously. Examples of these applications in biotechnology include, but are not
limited to, targeting receptors gene regulation, imaging and treatment.[48-55] Our ability to
control synthesis and functionalization of materials at the nanoscale allows for tailored design
and applications of nanotechnology in interdisciplinary research areas.
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Nanoparticles are typically classified into 2 types: naturally occurring or anthropogenic
nanoparticles.[56] Natural nanoparticles are ubiquitous and formed through organic physical,
chemical and biological processes such as hydrolysis, weathering, erosion, photochemical
reactions and many more. These types of nanoparticles include geogenic fullerenes, iron-oxides,
sea salt, some metals (such as silver and gold), magnetite and many more. Anthropogenic
nanoparticles are purposely manufactured to serve particular purposes and include metallic
nanoparticles, carbon nanotubes (CNTs), polymeric nanoparticles and many more. Although
there exists a myriad of fabrication techniques, these typically fall into two major categories: topdown or bottom-up approaches.[57-59] On one hand, the top-down approach involves
manipulation of a bulk sample to removal material and form a nanoscale structure. (ref) On the
other hand, a bottom-up technique entails construction of nanostructures from atomic or
molecular foundations. Moreover, both can methods are employed to design NPs with specific
properties for intended use.
Driven by innovations in chemistry and synthesis techniques, nanomaterials are
fabricated with varying properties that allow for construction of a vast mixture of nanoparticle
characteristics. These include: physical properties (size, geometry, hydrodynamic size, porosity);
surface properties (functionalization, hydrophilic/hydrophobicity, charge, density); targeting
moieties

(proteins,

aptamers,

targeting

antibodies);

and

chemical

composition

(superparamagnetic oxide nanoparticles, quantum dots, nanocages, carbon nanotubes).[60-62]
The increasing variety in the properties of each class of nanoparticles results is distinct in vitro
and in vivo profiles such as stability, toxicity, drug release kinetics, blood clearance, intracellular
localization and tissue accumulation. Furthermore, the capability to manipulate material
properties at the nanoscale level sets the foundation for the development of innovative diagnostic
and imaging agents for disease detection, as well as treatment.
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Nanoparticle-based medical applications
Drug delivery is widely studied in the field of nanomedicine, leading with the highest
number of commercialized products, publications and patents.[63] Diagnostically, nanoparticles
allow for detection at the molecular level, and therapeutically, they enable targeted delivery and
controlled release of agents. With an ever-increasing research impetus for the application of
nanotechnology in medicine, nanoparticles are under investigation for use in the diagnosis and
treatment of illnesses such as malignancies, inflammatory and cardiovascular diseases.[64, 65]
Therefore, objectives such as safety, sustainability and tissue-targeted delivery of therapeutics
and contrast agents are further studied to create more effective therapies.
Key objectives of delivery systems include release of therapeutics at the desired dose,
for a specified duration, and to the desired anatomic location. These objectives apply in the
setting any administration route, be it systemic, transdermal, oral, parenteral or pulmonary. Any
material recognized as foreign entering the bloodstream is absorbed by phagocytes with the
capability to remove them. However, phagocytes do not specifically absorb objects roughly
200nm or less, which allows nanoparticles to travel freely throughout the body.[66] The small
size of nanoparticles further increases their mobility by allowing for easier diffusion than solid
particles. Drug delivery has evolved drastically since initial accounts of sustained drug release
procedures in the 1970’s.[67] The field now includes new classes of delivery methods including
environmental (pH, temperature, osmosis), diffusion controlled, ligand or chemically controlled
conditions.[60, 65, 67-70]
Diagnostically, properties of elements such as iodine and barium with a high atomic
number (Z) have historically been used as contrast agents for imaging. These imaging
techniques utilize the high X-ray attenuation coefficients of these materials to produce improved
contrast.[71] The higher energy absorption coefficients, relative to surrounding tissue, allows the
presence of these materials to result in increased dose delivery to surrounding tissue; thereby
expanding the potential for the use of high-elements as contrast agents in a therapeutic setting.
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Metallic nanoparticles, specifically, have diverse applications in medicine, catalysis,
engineering, and several fields. This diversity is largely conferred by their optical, fluorescent,
electronic and magnetic properties. The variety of applications stem from two qualities: 1) surface
plasmon excitation that allows for examination of their distinct optical characteristics across the
vis-NIR band, and 2) surface modification to improve in vitro and in vivo properties.[72] Gold
nanoparticles are one of the most popular class of nanomaterials used in biomedical applications.

Figure 1.6: Design considerations for nanoparticle synthesis. Final nanoparticle construct
depends on the intended use. Properties such as type of material, size, shape and surface
functionalization can be tailored to optimize the function envisioned.
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Gold nanoparticles
Due to their unique chemical, optical, electronic and magnetic properties, gold nanoparticles
have wide applications in the field of bionantechnology. Dating back to the 5th century, B.C., gold
nanoparticles (AuNPs) were used for decorations of ceramics and as ingredients in medicinal
concoctions.[73] It wasn’t until 1857 that Michael Faraday first recognized that the optical
properties observed in structures containing the nanoparticles were due to the differences in the
size of particles; a difference which resulted in the variety of colours used for decoration of the
ceramics and glass.[74] Several contributions from Zsigmondy, Svedberg, Langevin and many
others illuminated concepts of synthesis, ultracentifugation and continuous Brownian motion that
led to better understanding and implementation of AuNPs in science and medicine. Biomedical
applications of AuNPs range from imaging, diagnostics, targeted delivery and therapy.
As a high Z element, GNPs have high X-ray attenuation coefficients that lead to improved
contrast. Additionally, the high energy absorption coefficients allow for increased dose deposition
when present in the irradiated medium. The interest in this application of AuNPs has increased
with over thousands of articles published to date. Early work by Hainfeld demonstrated AuNP
radiosensitization potential through uptake and tumor control with the combination treatment of
AuNPs with kilovoltage RT.[75] This resulted in theoretical and experimental studies to further
explore the radiosensitizing effects of AuNPs. The general consensus is that AuNPs sensitize to
ionizing radiation in both the in vitro and in vivo settings. This has been established for RT types
ranging from electrons, photons (keV and MV), to charged particles, which further supports the
broad clinical applicability of AuNPs.[76] However, macroscopic dose model predictions for the
level of radiosensitization effects of AuNPs underestimate the effects observed experimentally,
thereby hampering optimization.
AuNPs studies utilize varying formulations in size, shape and surface moieties which have all
demonstrated noteworthy effects on sensitization. Moreover, AuNP-mediated radiosensitization
is also dependent on the system studied, with varying responses among cell lines, as well as in
vivo model systems. Altogether, these uncertainties hinder the expansion of AuNPs into clinical
19

practice with key issues of particle development for optimal targeting, cost effective delivery and
validation mechanisms. The ideal AuNP design considers the type of disease and its
microenvironment, the biodistribution of the AuNPs in vivo, and the interaction with off-target
tissues.
In that regard, AuNPs afford a rigid, well-defined foundation for surface modification with
different moieties or targeting ligands. The synthesis of monodisperse AuNPs with varying sizes
and shapes is relatively straightforward.[77] UV-Vis spectrometry can easily detect the strong
surface plasmon peak, and dynamic light scattering can characterize the hydrodynamic size and
surface charge using Mie scattering. The optical properties of AuNPs also allows for designing
formulations of nanoparticles that can be tracked overtime for stability, and within in vivo systems.
Thorough characterization of the physiochemical properties, pharmacokinetics, biodistribution
and molecular mechanisms are required to set the foundation for future integration into clinical
practice.
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1.4 Thesis overview: hypothesis, objectives and structure
Despite recent advances in research, cancer remains the leading cause of morbidity and
mortality worldwide. Radiation therapy (RT), alone and in combination with other therapies,
affords a wide range of therapeutic options, with over half of all patients receiving RT at some
point in their treatment. The therapeutic efficiency of RT, however, is mainly limited by toxicity
and increasing resistance of cancer cells. Consequently, the study radiosensitizers has emerged
as a promising field to address these issues. Among these studies, the field of nanotechnology
plays a key role in both the therapeutic approach and as platforms for drug delivery. Gold
nanoparticles (AuNPs), in particular, have attracted increasing research interest for the physical
and chemical properties that lend these particles very well for use as radiosensitizers.
This thesis enterprise addresses a clinically pertinent need in cancer therapy for tumorlocalized radiation dose enhancement. The approach includes deep penetration of on-demand
triggered-release of nuclear-targeted gold nanoparticle formulations that strongly sensitize
tumors to radiotherapy. This would lay the foundation for a physically, biologically and preclinically characterized radiation response modulation strategy with the potential to be widely
applied as a turnkey class solution across multiple tumor types. The central hypothesis is that
AuNPs packaged in thermosensitive liposomes (TSLs) accumulate passively in the perivascular
space of tumors, and hyperthermia facilitates release of the gold nanoparticles deep into the
tumor parenchyma; and that cellular internalization, especially nuclear targeting, significantly
improves the efficacy of AuNP-mediated radiosensitization by directly modulating tumor radiation
response as a result of increased DNA damage from radiation therapy. I test this hypothesis in
the following chapters.
Chapters 2 – 4 explore the critical unanswered questions relating to the fate of fold
nanoparticles at the cellular level and consequent biological effects, as well as penetration of the
biophysical barriers of pancreatic cancer tumor models by the TSLs. The overall experimental
design is displayed in Figure x below. Chapter 2 reports the development of gold nanoparticles
and the sub-cellular localization of the conjugate nanoparticles. Chapter 3 examines the in vitro
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radiosensization capability of the gold nanoparticles and postulated mechanisms of local dose
enhancement. Chapter 4 ascertains the in vivo accumulation of the gold nanoparticle conjugates
with and without thermosensitive liposomes, and the tumor killing efficacy. Chapter 5 provides a
summary, discussion and potential future directions. The general design of this thesis is depicted
in Fig. 1.7.

Figure 1.7: Graphical thesis overview. Deidentified human pancreatic tumour cells are used for
evaluation for gold nanoparticle radiosentization in vitro, as well as to establish in vivo tumours
to assess their efficacy in combined treatment.
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Chapter II: Cellular nanoparticle distribution
2.1 Abstract
With increasing clinical interest in nanoparticles as drug delivery (clinical trials) or
treatment enhancement agents for cancer, mechanistic investigations of the physiochemical
properties can result in improved delivery strategies. In the context of radiation in which the main
target is DNA, it follows that targeting of nanoparticles to the nucleus can produce a pronounced
effect in terms of enhancing the effects of radiation. Here, we investigate the feasibility of
designing and fabricating gold nanoparticles capable of transport into the cell nucleus (Figure
2.1). We consider various strategies including nanoparticle parameters such as size and charge,
targeting moieties, conjugation chemistries, nanoparticle treatment time and cellular confluence
at the time of treatment. Panc-1 (pancreatic cancer cell line) is used as an original model and
these experiments are further validated in a second pancreatic cancer cell line (MiaPaCa-2), as
well as a normal pancreas cell line (HPDE). Final nanoparticle design consists of spherical gold
nanoparticles 4 to 5 nm in diameter of the core, with a final hydrodynamic size < 15nm as
measured by dynamic light scattering, and surface charge < +5mV as determined by zeta
potential. Optical density as measured by spectrophotometry serves as an initial surrogate
marker prior to further characterization. Imaging data using dark field microscopy, confocal
microscopy and transmission electron microscopy captures the cellular level distribution.
Inductively coupled plasma mass spectrometry quantitates the uptake of the nanoparticles.
Cellular fractionation and subsequent quantification of gold uptake further confirm sub-cellular
localization of the nanoparticles.
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Figure 2.1. Chapter II graphical overview. Synthesis, conjugation and characterization of AuNS.
Assessment of AuNS sub-cellular localization.

2.2 Introduction
Recent advances in the design of nanoparticles (NPs) has resulted in a broader number
of applications for imaging, drug delivery and therapeutics. [78-80] For gold nanoparticles
(AuNPs), these applications rely on the shape, size and surface functionality of the nanoparticles.
Furthermore, these characteristics are greatly partial to the physiochemical conditions at the time
of NP synthesis, such as reaction temperature, gold to reducing agent ratio, presence of
surfactants and stirring rate.[81] Moreover, effectual use of these particles necessitates
overcoming biological barriers, accumulation in specific tissues and subcellular compartments,
and prolonged circulation.[82, 83] As such, the properties of AuNPs commonly evaluated include
size, shape, interaction with light (usually via optical density measurements), surface charge and
surface chemistry or functionalization status.
Due to their notable scattering cross section (~10-10 cm2), metal particles can be imaged
under white-light illumination. The oscillating electromagnetic field of the light induces an
oscillation of free electrons in the metal NP with light exposure. The electron oscillation at the
particle surface results in a charge difference in the ionic lattice. This tnhe causes a dipole
oscillation in the direction of the electric field of the light. The specific frequency at which this
oscillation is at the maximum is known as the surface plasmon resonance (SPR).[84-86] The
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SPR results in a strong absorption of incident light measurable by UV-Vis (ultraviolet-visible)
spectrometry. Another optical property of metal NP is the total light extinction. This is the loss of
electromagnetic wave energy after passing through matter, and results from absorption and
scattering processes. Absorption occurs when the energy is dispersed due to inelastic
mechanisms. Scattering happens when the energy causes elections in the matter to oscillate
and emit photons at the same frequency as incident light (Rayleigh scattering) or at a shifted
frequency (Raman scattering). The SPR, total extinction and scattering are commonly studied
using Mie theory.[87] As alluded to, the SPR for metal particles, AuNPs in our case, can be tuned
across the visible spectrum and near infrared by simply altering the particle size and shape.[88,
89] As such, the interaction of AuNPs with light provides an accurate technique to evaluate and
track other properties such as size, shape and functionalization status.
Given that the main target of RT is cell DNA, we hypothesized that targeting the gold
nanoparticles to the nucleus with localization close to the DNA would result in an increased
incidence of DNA damage upon radiation. Therefore, we design 4-5nm gold nanospheres
(AuNSs) here to explore the mechanistic aspects of targeting them to the nucleus in vitro. In
particular, we examined the change in AuNS properties such absorbance, size (using dynamic
light scattering – DLS) and charge as we conjugated targeting moieties to the surface. In order
to achieve subcellular localization, the targeted AuNSs need to traverse the cellular membrane
and nuclear membrane, for the targeted particles. We underscore the utility of a nuclear
localization sequence (NLS) molecule at the surface of the AuNSs on subcellular targeting to the
cell nucleus.
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2.3 Results and discussion
Therapeutic applications of nanoparticles in cancer require either localization to the tumor
microenvironment or cellular internalization for in vitro studies to minimize effects from the
presence of particle in culture media. Here, we design experiments to evaluate the uptake of gold
nanoparticles within cells, and specifically, into the cell nucleus for the group conjugated with the
NLS.

Synthesis and characterization of AuNS conjugates
We synthesize 4-5nm gold nanospheres (AuNSs) as base particles for further
modification. The bare AuNSs are then conjugation with poly(ethylene) glycol (PEGylated) to
yield control particles (pAuNS), and further decorated with one of two peptide sequences to
generate either a second control particle group with a scrambled peptide sequence similar in size
and molecular weight to the NLS but consisting of different amino acids (sAuNS), or nucleartargeted nanoparticles (nAuNS) with an NLS. The conjugation schema is illustrated in Figure 1.
AuNS formation is confirmed using transmission electron microscopy (TEM) images revealing
monodisperse particles uniform in size (Figure 2.2). Notably, the PEGylated and further
conjugate groups of the AuNSs appear identical to bare AuNS on TEM imaging. Quantification
using the microBCA assay estimated 950-1000 peptides per gold nanoparticle.
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Figure 2.2. AuNS synthesis and characterisation. (A) Schematic of AuNS conjugation with
mPEG to create pAuNSs (top); bifunctional PEG (bottom) followed by coupling by the
EDC/NHS reaction to create sAuNSs or nAuNSs. (B) TEM images of synthesized AuNSs
demonstrating uniform and monodisperse particles. Scale bars 20nm and 100nm.
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Due to their optical properties, AuNP stability is easily assessed using the surface
plasmon resonance (SPR) band. The colour of the AuNS solution during synthesis is dependent
on the SPR, and can be an immediate indicator for particle size or aggregation prior to further
PEGylation. Ultraviolet-visible (UV-Vis) spectra confirm a peak absorption band (SPR) for the
bare AuNS (513 nm) in MilliQ water that resulted in slight red shifts upon PEGylation (pAuNS) at
514 nm and subsequently, a nuclear localization sequence (nAuNS) or a scrambled peptide
sequence (sAuNS) – 516 nm for both. These absorbance peaks remained stable with additional
synthesis and conjugation cycles as represented by the consistent standard deviation in
measurements (Figure 2.3 and Table 2.1).
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Figure 2.3: Spectrophotometric analysis of AuNS. UV-Vis spectra of AuNSs. There is a slight
red shift in peak absorbance observed from bare AuNS as the particle is PEGylated, then
conjugated with a peptide sequence.
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Table 2.1: AuNS characterization

AuNS Formulation

Peak Absorbance

Size

Zeta Potential

Bare AuNS

513 ± 3nm

5.28 ± 1.5nm

-14.7 ± 6.4mV

pAuNS

514 ± 3nm

11.56 ± 3.9nm

-3.54 ± 7.1mV

sAuNS

516 ± 3nm

13.95 ± 2.7nm

0.013 ± 6.1mV

nAuNS

516 ± 3nm

14.34 ± 3.1nm

2.81 ± 10mV

Peak absorbance on UV-vis spectroscopy, hydrodynamic diameter (size) on dynamic light
scattering and surface charge (zeta potential) on zeta potentiometry of different AuNS
formulations presented as mean ± standard deviation.

In addition to UV-Vis spectroscopy, dynamic light scattering (DLS) and Zeta-potential
measurements confirm electrokinetic properties of the AuNS conjugates. PEGylation generally
leads to an increase in hydrodynamic size by roughly 10 – 30 nm. Size measurements calculated
per DLS verify an increase in hydrodynamic diameter with PEGylation and subsequent
conjugation with either peptides used. The resultant particles suspended in water exhibit nearneutral surface charge (ranging from -3.54 to +2.93 mV zeta potentials). In fact, measurements
of absorbance and size reveal stable conjugates up to one-month post-synthesis, whereas zeta
potential measurements started trending upwards around three weeks post-synthesis (Figures
2.4 – 2.5, and Tables 2.2 – 2.4).
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Table 2.2: Stability of AuNS formulations per UV-Vis spectra
AuNS Formulation

Day of
Synthesis

Day 3 PostSynthesis

Day 7
(Week 1)

Week 2

Week 3

Week 4

Bare AuNS

513 ± 3nm

513 ± 3nm

512 ± 3nm

513 ± 3nm

514 ± 3nm

513 ± 3nm

pAuNS

514 ± 3nm

514 ± 3nm

514 ± 3nm

514 ± 3nm

514 ± 3nm

514 ± 3nm

sAuNS

516 ± 3nm

516 ± 3nm

516 ± 3nm

516 ± 3nm

516 ± 3nm

516 ± 3nm

nAuNS

516 ± 3nm

516 ± 3nm

516 ± 3nm

516 ± 3nm

516 ± 3nm

516 ± 3nm

Stability of AuNS formulations over time as determined by UV-vis absorbance spectroscopy.
AuNS formulations were stored at 4oC and peak absorbance was measured at different time
points up to 4 weeks from synthesis. Values are mean ± standard deviation.
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Figure 2.4: Size evaluation of AuNSs. Representative dynamic light scattering measurements
of AuNS formulations confirming progressive increase in size as bare AuNSs are decorated
with PEG and then the peptide sequence.

Table 2.3: Size stability of AuNS formulations per DLS measurements.
AuNS
Formulation

Day of
Synthesis

Day 3 PostSynthesis

Day 7
(Week 1)

Week 2

Week 3

Week 4

Bare AuNS

5.28 ± 1.5nm

5.7 ± 2.3nm

5.2 ± 2.4nm

5.9 ± 1.9nm

6.7 ± 2.0nm

9.87 ± 2.9nm

pAuNS

11.56 ± 3.9nm

11.4 ± 2.4nm

11.91 ± 3.1nm

11.46 ± 2.9nm

11.82 ± 2.6nm

11.57 ± 2.7nm

sAuNS

13.95 ± 2.7nm

13.72 ± 3.5nm

13.79 ± 3.1nm

14.09 ± 4.2nm

14.05 ± 3.3nm

13.87 ± 3.0nm

nAuNS

14.34 ± 3.1nm

14.27 ± 3.4nm

14.29 ± 3.4nm

14.43 ± 3.2nm

14.78 ± 3.7nm

14.57 ± 3.2nm

Stability of AuNS formulations over time as determined by dynamic light scattering. AuNS
formulations were stored at 4oC and hydrodynamic diameters were measured at different time
points up to 4 weeks from synthesis. Values are mean ± standard deviation.
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Figure 2.5: Surface charge evaluation of AuNSs. Representative zeta potential measurements
of AuNS formulations confirming near neutral surface charge when bare AuNSs are decorated
with PEG or the peptide sequence.

Table 2.4: Surface charge stability of AuNS formulations per zeta potential measurements.
AuNS
Formulation

Day of
Synthesis

Day 3 PostSynthesis

Day 7
(Week 1)

Week 2

Week 3

Week 4

Bare AuNS

-14.7 ± 6.4mV

-17.7 ± 13mV

-13.1 ± 9.3mV

-18.9 ± 5.1mV

-28.6 ± 7.1mV

-29.3 ± 8.9mV

pAuNS

-3.54 ± 7.1mV

-2.91 ± 10mV

-3.01 ± 11mV

-1.49 ± 12mV

-0.29 ± 10mV

1.25 ± 8.0mV

sAuNS

0.013 ± 6.1mV

0.98 ± 4.0mV

1.16 ± 7.3mV

0.013 ± 6.1mV

6.23 ± 4.8mV

4.53 ± 4.2mV

nAuNS

2.81 ± 10mV

1.14 ± 3.3mV

2.81 ± 10mV

2.93 ± 9.0mV

10.6 ± 6.1mV

11.0 ± 8.1mV

Stability of AuNS formulations over time as determined by zeta potentiometry. AuNS
formulations were stored at 4oC and surface charge was measured at different time points up to
4 weeks from synthesis. Values are mean ± standard deviation.
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The SPR band intensity and wavelength is stronger for noble metals, especially gold, and
dependent on factors affecting electron charge density at particle surface.[90, 91] These factors
include particle size, shape, composition and the surrounding medium dielectric constant. Any
variations in the SPR band are indicative of particle stability such that any changes in color of
the solution, or SPR band position and shape denote particle aggregation or size and shape
variations. As such, the consistency in solution color and absorbance peaks signify reliability in
the synthesis and conjugation techniques for every preparation as well as the stability of these
particles prior to experimental use, as evidenced in this chapter.

AuNS cellular toxicity and uptake
The cell membrane is a phospholipid bilayer that acts as a selectively permeable barrier
to control the entry and expulsion of substances in and out the cell.[92, 93] Passive and active
transport allow passage of materials through the membrane. Passive transport occurs via
diffusion down a concentration gradient whereas active transports requires adenosine
triphosphate (ATP) for movement against the concentration gradient. Charged biomolecules are
taken up through endocytosis, classified into phagocytocysis and pinocytosis. Pinocytosis, the
mechanism of internalization for small particles in the nanometer range, is further classified into
clathrin and caveolae-mediated, or clathrin- and caveolae-independent endocytosis.[94] The
size, shape, surface charge or functionalization and hydrophilicity or hydrophobicity further affect
cellular internalization, route of uptake and cytotoxicity of nanoparticles.
Although gold nanoparticles are biocompatible, surface ligands and charge can affect cell
uptake and viability. A previous study established no in vitro toxicity of gold nanoparticle
concentrations as high as 1.5 nM with minimal effect on cell proliferation over two doubling
times.[95] This study also demonstrated that serum-containing media significantly reduced the
internalization of AuNPs due to adsorption of the proteins to the AuNP surface, and interruption
of cellular membrane-AuNP interactions. Therefore, we test the effect of gold nanosphere
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(AuNS) treatment on cells using the colorimetric MTT assay evaluating metabolic activity via the
NAD(P)H pathway. Treatment with AuNSs alone showed no effect on cell viability up to 5 days
following treatment of Panc-1 and MiaPaCa-2 pancreatic cancer cells on an MTT assay (Figure
2.6a). The treatment concentration of AuNSs for further in vitro studies was chosen based on
these experiments and preliminary clonogenic assay results.
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Figure 2.6: AuNS cytotoxicity and uptake. (A) Cellular toxicity studies in Panc-1, MiaPaca-2 and
HPDE cells using the MTT assay. Fluorescent intensity measurements are normalized to the
values obtained in control (no AuNS-treated) groups. (B) ICP-MS measurement of gold uptake
in all three cell lines normalized to the cell count prior to sample preparation for analysis.
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While minimizing particle aggregation and protein adsorption, PEGylation also reduces
cellular internalization.[95] A 2009 study established a molecular with of 2 kDa for PEG, based
on optimal chain length and surface density saturation, resulted in the least uptake in an in vitro
macrophage study.[96] As such, this molecular weight of PEG is used for AuNS modifications in
all experiments. Additionally, a cell penetrating peptide (CPP), RGD in our case, is employed to
facilitate cellular uptake. However, following comparison with no CPP treatment that reveal
greater up uptake levels without the CPP, subsequent experiments were performed with no CPP
treatment. In both cell lines, inductively coupled plasma mass spectrometry (ICP-MS)
quantitative elemental analysis of gold noted greater gold uptake following sAuNS and nAuNS
treatment than pAuNS treatment ranging from 1 – 15 picograms/cell (Figure 2.6b).
Conjugation of AuNSs with biomolecules that anchor to cell surface receptors is a method
used to amplify internalization into cells. As briefly discussed, the major internalizationpathway
for non-targeted AuNSs is via receptor-mediated endocytosis (RME), evidenced by decreased
uptake at low temperatures or ATP-depleted conditions.[97-100] This method of uptake,
however, results in entrapment of the particles in intracytoplasmic vesicles followed by
degradation or excretion from the cell, which limits the potential applications. Delivery to
subcellular sites, such as mitochondria, golgi apparatus or endoplasmic reticulum, could improve
drug effect at the intracellular site action and minimize off-target consequences.
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Sub-cellular localization
The cell nucleus is an ideal target for drug delivery because it is the central focus of the
cell’s genetic information. For RT, the nucleus is of particular interest because DNA in cancer
cells is the main target for RT damage. In eukaryotic cells, the nucleus is isolated from the
cytoplasm by the double-layered nuclear envelope traversed by nuclear pore complexes (NPCs).
Specific ligands such as nuclear localization sequences (NLSs) or nuclear export sequences
(NESs) are required to transport macromolecules across NPCs.[101, 102] Proteins known as
karyopherins facilitate movement in (importins) or out (exportins) of the nucleus through the NPC
by binding to the macromolecule and docking it to the respective side of the NPC.[102, 103]
Therefore, attachment of macromolecules to NLS drives their accumulation in or around the
nucleus.
We utilize an NLS molecule derived from the Human Immunodeficiency Virus (HIV)
transactivator of transcription (TAT) peptide for nuclear targeting. We compare subcellular
localization of these gold nanoparticles targeted to the nucleus (nAuNS) to no particle treatment
(control) and treatment with either pAuNSs or sAuNSs. Qualitative dark field microscopy showed
a colocalization of nAuNS signal with a nuclear stain (DAPI) while a generalized cytoplasmic
distribution was observed in both Panc-1 and MiaPaCa-2 cells for pAuNS and sAuNS particles.
The spatial distribution of gold within cells was qualitatively different with dark field microscopy
of both cells showing localization of the nAuNSs in the nucleus (stained with DAPI) while the
sAuNSs showed a more generalized cytoplasmic distribution (Figures 2.7 – 2.8).

37

Darkfield

Merge

nAuNS

sAuNS

pAuNS

Control

DAPI

Figure 2.7: MiaPaCa-2 AuNS localisation. Uptake studies qualitatively assessed using dark
field microscopy confirmed minimal pAuNS internalization but abundant sAuNS and nAuNS
uptake, with greater co-localization of nAuNSs with nuclear DAPI stain than pAuNSs or
sAuNSs.
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Figure 2.8: Panc-1 AuNS localisation. Similar to MiaPaCa-2 results, Panc-1 dark field studies
confirmed minimal pAuNS internalization but abundant sAuNS and nAuNS uptake, with greater
co-localization of nAuNSs with nuclear DAPI stain than pAuNSs or sAuNSs.
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This dichotomy was further validated when cellular cytoplasmic and nuclear fractions
were separated, as confirmed by Western blot, and gold uptake was higher in the nucleus with
nAuNSs than pAuNSs or sAuNSs (Figure 2.9). Gold uptake in cell fractions is normalized to
protein content, explaining the higher gold levels in the nuclear compared to the fractions. TEM
images of Panc-1 and MiaPaCa-2 cells showed greater numbers of nAuNSs outside the
endosomes and in the nucleus than pAuNSs and sAuNSs. Representative images are shown in
Figures 2.10 – 2.11.
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Figure 2.9: Subcellular localization of AuNSs. (A) Western blot confirmation of subcellular
fractionation with vinculin denoting cytoplasmic fraction, and p84 and histone H3 indicating
nuclear fractions. (B – C) ICP-MS quantification of elemental gold content in cytoplasmic vs.
nuclear fractions in all three cell lines normalized to the cell count prior to sample preparation
for analysis, or amount of protein per Western blot analysis.
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Nuclear pore

Nuclear
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Figure 2.10: Subcellular localization of AuNSs in Panc-1 cells. (A) TEM images of control cells
with no particle treatment with a higher magnification close-up image as well. (B)
Representative image of non-targeted pAuNSs in cells at low and high magnifications. Purple
arrowheads point to AuNSs. (C) TEM images of nAuNS-treated cells with high magnification
images of AuNSs near the nuclear membrane. Scale bars noted in each figure.
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A

B

Figure 2.11: Subcellular localization of AuNSs in MiaPaCa-2 cells. Cells treated with pAuNS (A)
and nAuNS (B) demonstrating nuclear uptake by nAuNS and cytoplasmic sequestration of
pAuNS. Magnification noted by scale bars and AuNSs marked by purple arrowheads.
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For cancer, nuclear-targeting is ideal for various therapeutics including chemotherapy
because the mechanism of action is through direct interaction with DNA or through inhibition of
replication enzymes such as topoisomerase prevent cell proliferation.[104, 105] However, this
requires drug transport into the tumor microenvironment, through the cell plasma membrane,
and finally the nuclear membrane consisting of pores on the order of nanometers.[106] We
demonstrate here that conjugation of a TAT-derived NLS molecule to AuNSs successfully
localizes them to the nucleus of pancreatic cancer cells, even to a greater extent than normal
HPDE cells. These results support the notion of differential uptake of AuNSs in normal vs cancer
cells at the whole cell and subcellular lever in terms of the nucleus. Furthermore, this sets the
groundwork to test our hypothesis of enhanced radiosensitivity with nuclear-localized AuNSs vs.
AuNSs sequestered in the cytoplasm or tumor microenvironment.
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2.4 Conclusion
Clinical application, drug penetration, intra-tumoral accumulation and systemic toxicity
are a few of the various obstacles that plague effective adaptation of nanoparticles for cancer
therapy. These factors are heavily influenced by the design of the nanoparticles which determine
their fate, behavior and effects in living organisms. The stability of nanoparticles is fundamental
for maintenance of physicochemical factors in vitro as well as in vivo. Optimization of parameters
such as size, surface charge, and targeting ligand density is required to achieve effective delivery
and subsequent biological response. The main objective of this chapter is to establish the
stability, biocompatibility and localization of the conjugate AuNSs for further testing in the
following chapters.
Similar to bulk gold, AuNPs normally exhibit low in vitro toxicity regardless of size or
geometry.[97] Cells internalized concentrations up to 100 m with no measurable toxicity of
AuNPs with negative or neutral capping agents such as citrate, biotin, cysteine or glucose. At
concentrations as low as 10 nm, however, AuNPs capped with cetyltrimethylammonium bromide
(CTAB) were found toxic to the same cells.[107] CTAB is quaternary ammonium surfactant
commonly used to stabilize AuNPs resulting in a cationic surface charge. Although cationic
AuNPs induce toxicity to a greater extent than their anionic counterparts, this observation is
dependent on the cell line under study.[108, 109] The charge of AuNS particles designed in this
aim remained stable following synthesis with a surface charge near neutral, as supported by the
zeta potential measurements.
Most bare nanoparticles remain stable in deionized water due to charge repulsion, as is
the case for the fabricated bare AuNSs here. Addition of salts and proteins can lead to charge
screening and adsorption, shielding surface charge which results in aggregation. This is
observed for the bare AuNS once added to cell culture media containing proteins. Poly (ethylene
glycol) (PEG) is widely utilized for modification of several compounds for biomedical
applications.[110-112] Grafting with PEG renders adjacent nanoparticles less susceptible to
aggregation induced by the presence of salts and serum because it forms extended layers that
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maintain separation between the particles. Engraftment of PEG to AuNPs is a popular approach
to bestow steric stability to AuNPs and the increased circulation in vivo through evasion of
macrophage recognition as foreign entities. Additionally, in vivo applications of AuNPs require
dilution in solutions such as phosphate buffered saline (PBS) in which PEGylation prevents saltinduced aggregation. Besides the bare AuNSs in these studies, the resultant particles remain
consistent in size, shape and with near neutral charge across various synthesis batches and over
weeks at time. This speaks to the robustness of our design protocol and the stability of the final
constructs.
Further underscoring stability, the AuNSs remain evenly distributed in phosphate buffered
saline (PBS) and cell culture media solutions containing proteins for over 48 hours at room
temperature, 4 C and 37 C with no visible signs of aggregation. Cell treatment consists of diluting
AuNS solutions with cell culture media to a given concentration (optical density units – OD) prior
to the addition to the cells. Consequently, AuNS interaction with cells is based on Brownian
motion of the particles in the media over the treatment time period and the surface ligands.
Untargeted nanoparticles are mainly internalized via receptor-mediated endocytosis (RME) –
also known as clathrin-mediated endocytosis, and very rarely through passive diffusion for
slightly cationic particles.[97, 100] This observation is supported by similar uptake levels for
sAuNS and nAuNS conjugates compared to pAuNS.
All in all, active targeting dictates that particle size for optimal nuclear delivery of AuNPs
should not exceed ~30 – 50 nm. Now that particle stability, biocompatibility and nuclear targeting
is established, the next step is to evaluate the radiosensitization potential of the gold nanosphere
(AuNS) conjugates in vitro. In Chapter III, we explore the ability of the AuNSs localized to the
nucleus of tumour cells to enhance the effects of radiation to a great extent than AuNSs in the
cellular cytoplasm. Based on the data presented here and previous studies, dose enhancement
in the area surrounding the AuNS is the inevitable consequence of irradiating any medium
containing the nanoparticles.
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2.5 Supporting information
Additional characterization performed with the help of collaborators further confirmed
synthesis and purification of AuNSs. First, mass spectrometry imaging was performed with the
help of Dodge Baluya at the core. This is to corroborate the characterization studies that the
peptide is indeed attached to the AuNS and not suspended in solution. Figure 2.12 displays the
spectra of several solutions. Although the specutrum for the NLS peptide shows a peak at 1559
(A), this peak is shifted to 1603 when after conjugation to an AuNS. This is consistent with
conjugation to both 5 nm (synthesized in-house) and 20 nm (purchased from NanoHybrids).

Figure 2.12. AuNS mass spectrometry imaging. Spectra of NLS and AuNS solutions to confirm
conjugation as follows: (A) NLS, (B) Bare 5 nm AuNS), (C) PEGylated 5 nm AuNS, (D) 5 nm
AuNS conjugated with bifunctional PEG prior to peptide addition, (E – F) 5 nm AuNS from
separate synthesis batches, (G) Bare 20 nm AuNS, and (H) 20 nm nAuNS with peak at 1603,
similar to E and F.
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Energy-dispersive X-ray spectroscopy (EDX) was performed by Onur Sahin at Rice
University to confirm purification of conjugation AuNS formulations from the bare AuNS solution.
Displayed in Figure 2.13 below are EDX sample and spectrum images of the synthesized bare
AuNS (top) and filtered nAuNS (bottom). The S component detected if from sulfur that is present
in the wafer on which the samples are placed. The Cl and Na detected are from the reagents of
AuNS synthesis which are notably absent in the nAuNS sample below.

Figure 2.13. EDX analysis of unconjugated and conjugated AuNS. Top – Bare AuNS sample
image and associated spectrum showing presence of synthesis reagents. Bottom – nAuNS
sample image and associated spectrum with highest detection of Au and no reagent elements
detected.
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2.6 Materials and methods
General protocols such as cell culture or imaging, as well as additional details are outlined
in the appendix.

AuNS synthesis, conjugation and characterization
Gold nanospheres (AuNSs) were synthesized using a bottom-up approach through
reduction of hydrogen tetrachloroauric acid (HAuCl4) with sodium borohydride (NaBH4) through
a modified protocol used by Martin et al.[113] Briefly, equal molar amounts of NaBH4 and HAuCl4
dissolved in Milli-Q water were combined while stirring with a magnetic stirrer. Volumes were
scaled up depending on the needs of the experiment. Methoxy-polyethylene glycol 2000 thiol
(mPEG-2K-SH) and bifunctional thiol polyethylene glycol amine (NH2-PEG-2K-SH) purchased
from NanoCS were added to AuNS solutions at 4oC and the reactions allowed to occur for 24-48
hrs

to

PEGylate

the

particles.

Two

peptides,

a

nuclear

localization

sequence

(GRKKRRQRRRPQ) and another peptide with similar molecular weight (Pyr-LYENKPRRPYIL),
were further conjugated to the particles with the bifunctional PEG. Ultraviolet-visible (UV-vis)
spectroscopy, dynamic light scattering (DLS) and zeta potential measurements were used to
characterize AuNS during and after synthesis.

AuNS toxicity and uptake studies
All experiments were performed by first plating cells at a density of 50,000 cells/mL
followed by a 24 hr incubation period to allow for cell attachment. Cells were then treated
according to assigned groups (control, pAuNS, sAuNS and nAuNS) for 24 hrs, and rinsed 3 times
with phosphate buffered serum (PBS). Uptake studies were performed in T75 flasks with cells
trypsinized following 3 PBS rinses and pelleted for digestion with aqua regia for ICP-MS analysis.

Nanoparticle cytotoxicity was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) kit (Roche, Sigma-Aldrich). Studies were carried out by
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plating cells in 96-well plates, followed by treatment, rinsing and allowing the cells to grow for
120 hrs. Following this incubation period, MTT reagent (5 mg/mL) was added to cells, incubated
at 37°C for 4 hrs in the dark and formazan crystals were dissolved using DMSO. The absorbance
was measured on a plate reader (Cytation™ 5 Cell Imaging Multi-Mode Reader, BioTek
Instruments) at an excitation wavelength of 590 nm and normalized to respective control cells.
Each experimental treatment group was tested in triplicate for each concentration, and with 2
separate AuNS synthesis batches.

Subcellular localization
Cellular fractionation was performed using the subcellular protein fractionation kit for
cultured cells from ThermoFisher (Cat #78840). Western blot analysis was performed courtesy
of the Welsch lab at UT MD Anderson cancer center. Briefly, protein content in the cytoplasmic
and nuclear lysates were quantified using the Bradford assay. Samples were then aliquoted for
Western blot analysis and quantification of gold content by inductively coupled plasma mass
spectrometry (ICP-MS).
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Chapter III: in vitro radiosensitization
3.1 Abstract
A fundamental tenet of cancer nanomedicine is to effectively deliver therapeutics
to cancer cells to improve anti-tumor activity and reduce the collateral effects in normal tissues.
Here, we report combination therapy using nuclear targeted gold nanoparticles coupled with
radiation therapy for pancreatic cancer treatment. The nanoparticles accumulate in the tumor
microenvironment via the enhanced permeability and retention effect, while a nuclear localization
sequence conjugated to the gold nanoparticle drives uptake into the nucleus of the tumor cells
as presented in Chapter II. Here, we demonstrate that nuclear localization of gold nanoparticles
boosts the effect of radiation therapy when compared to treatment with radiation therapy alone,
or in combination with nanoparticles sequestered in the cell cytoplasm. This sensitization results
from the production of secondary electrons (Figure 3.1) following the interaction between gold
and radiation and is mediated, in part, by increased production of reactive oxygen species and
DNA double strand breaks. Furthermore, we establish the effects of combined therapy on cell
metabolism, mitochondrial membrane potential and the cell cycle to further elucidate the
mechanism of gold nanoparticle-mediated radiosensitization.
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Figure 3.1. Chapter III graphical representation. Gold nanoparticle-mediated radiosensitization
postulated to occur via secondary electron production. Adapted from illustration by Briggs S,
and Hattar, K. Evolution of Gold Nanoparticles in Radiation Environment [114]

3.2 Introduction
Irradiation of tumours laden with high atomic number (Z) materials such as gold results
in radiation dose enhancement via increased secondary electron production from nanoparticleradiation interactions.[75, 115, 116] The augmented density of ionization localized near or at the
surface of the AuNPs leads to enhanced probability of lethal damage to cells containing the
materials by transiently increasing the radiation-interaction cross section in the target tissue. A
study 40 years ago demonstrated the radiosensitization potential of iodine in cultured cells.[117]
This was later validated in vivo when injection of iodine into tumors followed by radiation resulted
in roughly 80% suppression of tumor growth in mouse models.[118] Gold has been pursued as
a radiosensitizer given its higher Z than iodine (Au, Z = 70 vs. I, Z = 53) and biocompatibility.[75]
Studies investigating the concentrations of high Z materials with radiation found that in order to
achieve radiosensitization, higher concentrations of iodine and gold (~5mg/g) were required.[75,
119]
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When the gold nanoparticles (AuNPs) were internalized in vitro, however,
radiosensitization effects were observed at concentrations as low as 10-6 mg/g.[115] These
results are consistent with previously published work demonstrating in vitro sensitization with
AuNP concentrations of ~10-3 mg/g at both kilovoltage (kV) and megavoltage (MV) energies of
radiation.[120] Based on these observations, it is possible to achieve radiosensitization effects
at considerably lower concentrations, given intra-cellular or sub-cellular accumulation of AuNPs.
Although the mechanism of radiosensitization at such low concentrations is not well understood,
it is generally accepted that the efficacy in vivo reported is attributable to an increase in
photoelectric absorption interactions due to the high Z of gold. The high Z increases the scattering
cross section and production of resulting in greater physical damage to tumour cells, as well as
endothelial cell lining the blood vessels. The damage observed via production of photoelectrons
and Auger/Coster-Kronig electrons, however, was observed with large quantities of gold on the
order of g gold/kg body weight. With this amount of gold, the mouse turned blackish blue following
injection, reinforcing that the tumor gold content is generally an index of tumor vascularity with
the AuNPs serving as contrast agents.
The amount of gold injected, content in tumor, timing of radiation (2min following injection)
and radiation used (26 Gy using 250 kVp X-rays) make this approach clinically impractical.
Nevertheless, this report laid the foundation for more in-depth evaluation of AuNP-based
radiation dose enhancement, and with it, active targeting strategies of AuNPs. We examine the
passive cell uptake and active nuclear targeting in the previous chapter. Here, we investigate the
radiosensitization potential of nuclear localization as well as the mechanisms by which radiation
dose enhancement occurs. Additionally, we explore the biologic effects of the quality of RT
through linear energy transfer (LET) and radiobiolical effectiveness with the addition of AuNSs
to the treatment regimen.
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3.3 Results and discussion
Optimizing design of AuNPs for radiosensitzation requires knowledge of the
physiochemical interactions of nanoparticles with cells in culture and tissues, as well as the
changes in radiation treatment instigated by the presence of the particles in the treatment field.
Additionally, the physical mechanisms of dose enhancement are contingent on the radiation
modality. In this chapter, we explore the radiosensitization potential of the nAuNSs with different
types of radiation, as well as the various processes by which dose enhancement occurs.

Clonogenic assays
The clonogenic assay is the classic in vitro cell survival assay that evaluates cell death
based on a single cell’s ability to produce a colony, defined as at least 50 cells. Simply, singlecell suspensions of the tumor cells are prepared from each treatment group (control, pAuNS,
sAuNS or nAuNS at each RT exposure), and plated under identical conditions. We plate a larger
number of cells with increasing RT dose in anticipation of greater cell kill with the higher RT dose.
After the incubation period, we determine the plating efficiencies in each treatment group and
calculate the surviving fractions. This is outlined in the supporting information.
We assess the radiosensitization potential using an orthovoltage RT beam (320 kVp
XRAD320). Clonogenic survival analysis noted that neither pAuNSs nor sAuNSs sensitized
either cell line to radiation. However, nAuNSs sensitized both cell lines to radiation with dose
enhancement factors (DEFs) calculated at the 10% surviving fraction of 1.17±0.01 and 1.31±0.04
for Panc-1 and MiaPaCa-2 cells, respectively. (Table 3.1) Representative survival curves are
shown in Fig. xa and xc, with representative colony images in Figure 3.2. Based on the linearquadratic (LQ) model, the cell survival assessment results in a linear curve with a β=0 for the
nAuNS combine with RT treatment groups in both cells. The linear curves are reminiscent of the
response of mammalian cells typically observed with irradiation using higher linear energy
transfer (LET) radiation (LET > 10keV/μm), or inhibition of DNA damage repair processes. These
results demonstrate modulation of the response to low LET radiation.
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Table 3.1: Dose enhancement factors and radiobiological effectiveness of combined AuNS plus
RT therapy. All data presented as mean ± standard deviation.
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Figure 3.2: Clonogenic survival analysis. Clonogenic survival curves of Panc-1 (A) and
MiaPaCa-2 (B) cells with representative images of stained colonies for each cell line. Results
confirm radiosensitization with pAuNS, sAuNS and nAuNS with the greatest radiosensitization
being with nAuNS.
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Radiosensitization potential with various RT sources
Observable effects of AuNP-mediated radiosensitization were originally postulated to
occur with high gold concentration and kilovoltage photon treatments. This physical phase is a
result of interactions between charged particles and atoms in the medium. The photoelectric
cross section of gold for kV photons is larger than that in soft tissue, given the L- and K-shell
electron excitation energies for gold. Additionally, the emissions of the inner shell elections
produce a cascade of low energy Auger and Coster-Kronig electrons that deposit the energy in
close proximity to the AuNP. However, in order to prove the potential for clinical translation, the
radiosensitization potential is also shown in a megavoltage photon beam, which is the most
commonly utilized RT modality for cancer therapy, and protons.
Consequently, we evaluate the effect of AuNS treatment combined with a variety of
radiation modalities. Clonogenic cell survival assays are performed to evaluate the
radiosensitization effect after irradiation with 320-kVp X-rays,

137

Cs-137,

60

Co, 6 MV and 100

MeV protons (LET 2.5 and 7.8 keV/µm). These studies reveal significantly higher radiation DEFs
at 10% survival fraction for nAuNS compared to pAuNS for all beams assessed. Protons with
higher LETs resulted in greater clonogenic cell death in comparison to low LET protons, and
nAuNS further increased radiosensitization whereas pAuNS do not. This further supports that,
across a spectrum of radiation energies and LETs, nuclear-targeted gold nanoparticles enhance
radiosensitization beyond that achievable with strictly intracytoplasmic gold nanoparticles. These
data are represented in Table 3.2. We seek to understand the underlying mechanisms of
radiosensitization in the following sections at the chemical and biological phases.
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Table 3.2: Radiation enhancement factors as a function of LET.

Source

LET (keV/µm)

REF for pAuNS REF for nAuNS

Cs-137

0.5-0.8

1.03

1.10

Co-60

0.2

1.14

1.38

250 kVp

2

1.07

1.35

6 MV

0.35

1.07

1.22

Proton

2.58

1.04

1.21

Proton

7.8

1.08

1.16

Reactive oxygen species
Damaging effects of radiation principally result from the ability to ionize or eject electrons
from molecules within cells. A majority of the biological damage, however, is produced by the
ejected elections which cause further ionizations during their collision with other molecules. This
ionization and excitation disrupt chemical bonds and form fragmented molecules known as free
radicals.[121] These free radicals are highly reactive and instigate a cascade of reactions that
eventually restore the overall electronic charge equilibrium. This chemical phase is underscored
by the competition between scavenging reactions with molecules that inactivate the free radicals
and the cascade of interactions to yield stable chemical changes to the molecules. Oxygen is
relatively susceptible to radical formation such as hydroxyl ions, hydroxyl radicals, peroxide,
hydrogen peroxide (H2O2) or superoxide ions.

58

Relative Luminescence Units

A

Panc-1
Control

10

*
*

pAuNS

*

sAuNS

1

nAuNS
Positive Control

0.1
no RT

B

Relative Luminescence Units

NAC

*

+RT

MiaPaCa-2

10

Control
*
*

*

NAC
pAuNS

*

sAuNS

1

nAuNS
Positive Control
0.1
no RT

+RT

Figure 3.3: Reactive oxygen species production. ROS production in Panc-1 (A) and MiaPaCa-2
(B) cells treated with AuNSs with or without RT. No difference in ROS production observed in
groups treated with pAuNS, sAuNS or nAuNS.
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Free radical reactions transpire within a few milliseconds of radiation exposure. As such,
we employ several design aspects to measure the effects of AuNS presence in the cells. The kit
chosen measures H2O2 levels because various ROS are converted to as a final product, and it
has the longest half-life to maximize detection. Although we found a statistically significant
difference in ROS production between the control and AuNS-treated groups (p<0.01), there was
no difference between the nAuNS and non-nuclear targeted AuNS groups (pAuNS and sAuNS).
Treatment with N-acetylcysteine, a glutathion precursor, results in a statistically significant
decrease in H2O2 detection for both control and RT-treated experimental groups. Based on these
results, we expect that any downstream ROS-mediated damage is independent of the type of
conjugate in the AuNS-treated groups.

DNA strand break assessment
All subsequent processes progressions following the physical and chemical phases make
up the biological phase, which generally begins with enzymatic reactions to the damage
produced in the physical and chemical phases. This includes repairing lesions created in several
cell components, especially DNA. Due to importance of DNA and complexity of replication for
cell proliferation, several mechanisms of repair exist to maintain DNA integrity. For damage
couased by ionizing radiation, amino acid bases are repaired via base excision repair (BER),
single strand damage by single strand break repair (SSBR), and double strand breaks (DSBs)
though either homologous recombination (HR) or non-homologous end-joining (NHER). Studies
have shown that other repair processes, such as mismatch repair (MMR) and nucleotide excision
repair (NER), play a minor role for RT.[122] This DNA damage response (DDR) is initiated by
recruitment of several proteins to the site of damage.
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Figure 3.4: DNA DSB evaluation. (A) DNA double strand break formation assessment using
53BP-1 and gH2AX immunofluorescence staining. Quantitative analysis of the number of 53BP1 (B) and ɣH2AX (C) foci per nucleus at different time points following no RT, 2 Gy and 4 Gy.
ns = not significant; * = p <0.001.
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One of the first events in this cascade of events is phosphorylation of the H2AX protein
into ɣH2AX. As such, we measure the expression and disappearance of this protein, along with
53BP-1, as surrogates in order to assess the effects of the AuNSs on the kinetics of DNA DSBs.
We evaluate DNA DSBs through immunofluorescence analysis of gH2AX and 53BP-1 foci
generated in the nuclei (Figure 3.4a), and found no difference in expression for control and AuNStreated groups in the absence of RT. However, 2 Gy RT resulted in increased levels of 53BP-1
foci at early timepoints (Figure 3.4b) with a gradual decline to normal by 24 - 48 hrs post-RT
(p<0.001). This was more pronounced with nAuNS than the other AuNSs. Greater numbers and
longer persistence of foci were noted after 4 Gy RT, with preservation of foci for up to 48 hrs
post-RT in the nAuNS treatment group (p<0.001). Similar results were observed for gH2AX foci
(Figure 3.4c). Additionally, we utilize the comet assay to determine the extent of DNA damage
beyond DSBs identified via foci staining.
Single cell gel electrophoresis, also known as the comet assay, permits evaluation of
DNA damage at the single cell level. We perform the assay under alkaline conditions in order to
detect the cumulative DNA damage from single-strand breaks, cross-linking and incomplete
repair sites in addition to double strand breaks. Furthermore, we distinguish the effects of AuNS
treatment with or without RT on producing this DNA damage. We report these effects in
measurements of both tail length and tail moment (Figure 3.5). Overall, combined AuNS
treatment with RT resulted in significantly longer tail length and higher tail moment
measurements, with nuclear targeting exerting the greatest effect with RT. Statistical analysis
reveals significant differences in treatment groups, as indicated on the graphs, with p values as
follows: no RT vs RT only (p < 0.02), sAuNS vs. nAuNS (p = 0.0004) and p < 0.0001 between all
other groups. These observations affirm the hypothesis that nuclear targeting of AuNSs results
in higher DNA damage.

62

B

Length (µm)

C

Comet Assay: Tail length
*

80

*

60

*

Control
pAuNS
sAuNS
nAuNS

*

40

D

20

Arbitrary Units (AU)

A

Comet Assay: Tail moment
600

*
*
*

400

*
200

0

0
no RT

no RT

with RT

with RT

Figure 3.5: Comet assay analysis. Results of alkaline single cell gel electrophoresis. (A)
Representative DAPI stained cells from no RT treatment group and (B) representative image
from RT-treated group. Analysis of (C) tail length and (D) tail moment measurements from
minimum n = 50 from each experimental group.

63

DNA repair analysis
The increased number in DSB foci present, increased DNA damage measurements from
the comet assay, and the loss of the shoulder in the cell survival curve suggest that inhibition of
the DNA repair process might be at play. In order to rule out the possibility that the enhanced cell
kill might be a result of DNA repair inhibition by the AuNSs, we perform a split-dose assay as
shown in Figure 3.5. We fractionate a single 4 Gy RT dose into 2 x 2 Gy doses separated by 24
hours. This provides ample time for DNA DSB repair to occur prior to the second dose. The
surviving colonies and recovery ratios are represented in Table x. Given the higher survival with
the fractionated RT regimen relative to the single higher dose, we conclude that the presence of
these AuNSs, even in the nucleus, do not significantly hamper DNA repair. This is further
validated by the calculated recovery ratios that indicate no decrease relative to the in the AuNStreated groups relative to the RT only group (Table 3.3). Recovery ratios are obtained by diving
the surviving fraction for the single dose by split dose.
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Table 3.3: Recovery ratios for split dose assay.

Cell type

Treatment

Panc-1

Control

0.2969

0.3943

1.328

pAuNS

0.2529

0.3904

1.544

sAuNS

0.2528

0.3797

1.472

nAuNS

0.1365

0.2739

2.001

Control

0.3020

0.4053

1.342

pAuNS

0.2656

0.3587

1.351

sAuNS

0.2707

0.3684

1.361

nAuNS

0.2160

0.2908

1.346

MiaPaCa-2

Single dose SF
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Split dose SF

Recovery Ratio

Cell cycle evaluation
The second crucial effector pathway, following H2AX phosphorylation, is cell-cycle
checkpoint activation. RT exposure results in delays in progression through the G1, S and G2
phases of the cell cycle.[123] Many tumour cells contain genetic mutations such as p53 or
BRCA1 that render several of the checkpoints disabled. The late G2 checkpoint, however, has
been shown to affect radiosensitivity because it is predominantly ATR dependent. As such, we
carry out cell cycle analysis at several time points following a single 4 Gy dose of RT. Generally,
cell cycle analysis also shows minimal effects of AuNS treatment (nuclear targeted and nontargeted) alone across all three cell lines (Figures 3.7 – 3.10). Of all phases of the cell cycle, the
S-phase appears least affected by RT exposure across all three cell lines. The percentage of
cells in sub-G1 is independent of RT exposure, and relatively low for HPDE and Panc-1 cell lines
(< 6%) but slightly higher for MiaPaCa-2 (~15% at select time points). The effects on cells in the
S-phase suggest less importance in HPDE and Panc-1 cells, whereas MiaPaCa-2 show an initial
increase in the percentage of cells followed by a decline. This is in line with our observation of
faster doubling time with these cells (20 – 24 hrs) compared to the Panc-1 (30 – 48 hrs) and
HPDE cells (48 – 72 hrs).
RT treatment results in an increase in the percentage of cells in the G2M phase
appreciable in all cell lines but especially notable for HPDE and MiaPaCa-2. Interestingly, this
increase is prominent at earlier time points (12 hr and 24 hr) for both cancer cell lines yet
persistent up to 120 hours post-RT for the HPDE cell line. This suggests a more efficient and
sensitive mechanism for DNA damage detection and DDR is in effect for the normal cell line
compared to the cancer cell lines. The changes in the percentage of cells in G2M is inversely
correlated with those in G0-G1. For HPDE, this is particularly noteworthy as the decrease in the
percentage of cells in G0-G1 drastically decreases and remains low up to the 120 hrs tested here
meanwhile, the percentage of cells in G2M increases and remains elevated. This change is
observed for MiaPaCa-2 cells as well, however, obvious at earlier timepoints with general return
to baseline levels at 48 hours onward. These differences are a bit more nuanced in the Panc-1
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cells. Although there is a general change (G2M increase vs G0-G1 decrease) with RT exposure,
there is no temporal correlation with or without RT. This also follows our observation that Panc1 cells are less radiosensitive given the wider distribution of cells in the cell cycle phases. We
follow-up up these studies with evaluation of the effects of AuNS treatment and RT exposure on
cell metabolism.
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Figure 3.7: Cell cycle evaluation – HPDE. Cell cycle distribution for AuNS treatment groups at
several time points with no RT exposure and following 4 Gy RT exposure. Trypsinized cells are
stained with propidium iodide and flow cytometry used to measure DNA content.
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Figure 3.8: Cell cycle evaluation – Panc-1. Cell cycle distribution for AuNS treatment groups at
several time points with no RT exposure and following 4 Gy RT exposure. Trypsinized cells are
stained with propidium iodide and flow cytometry used to measure DNA content.
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Effect of AuNS treatment on cell metabolism and mitochondrial membrane potential
The Warbug effect was coined decades ago based on the observation that cancer cells
produce excess lactic acid in the presence of oxygen.[124] The switch from maximal ATP
production through oxidative phosphorylation to balancing energic needs with substrate
availability for rapid reproduction is termed bioenergetic reprogramming. This is dictated by
mitochondria along with several fundamental parameters such as energy production, ROS
generation, synthesis of biosynthetic precursor and initiation of apoptosis.[125, 126] Therefore,
mitochondria are vital in various aspects of tumour progression. We study mitochondrial function
was using the Seahorse assay to measure the oxygen consumption rate (OCR) and the
extracellular acidification rate (ECAR), a surrogate measure of glycolysis.
Seahorse assay results reveal that the OCR of pancreatic cancer cells differs from that
of the normal HPDE cell line, as well as the fact that ECAR is decreased in AuNS-treated groups
relative to the normal cells. Data demonstrate decreased OCR and ECAR for AuNS treated cells
before RT exposure relative to the untreated controls (Figure 3.10) This decline is further
emphasized with RT. These effects, however, did not vary significantly between nuclear targeted
and non-targeted GNP treatment groups. This is consistent for both cancer cell lines, as well as
the normal HPDE cells. As well, AuNS treatment reduces the reserve capacity of normal and
pancreatic cancer cells with or without RT. This is especially true for the normal pancreatic cancer
cell line displaying the highest reserve capacity of the three cell lines. ECAR levels, though closer
in range for all three cell lines, decrease with nAuNS treatment. Of note, baseline OCR but not
ECAR levels are lower for the HPDE cells than the cancer cells as expected.
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Figure 3.10: Seahorse assay for cellular metabolism. Effects of AuNS treatment on OCR
without RT (A) and 1 following RT exposure (B). Similar results on ECAR with (C) and without
(D) RT exposure. Arrows indicate points at which reagent is added during the assay.
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This observation is further validated by the study into the effects of the AuNSs on the
mitochondrial potential. Mitochondrial activity measured by the membrane potential following 24
hours of AuNS treatment without RT shows no statistically significant difference between control
vs AuNS-treated groups. After RT exposure, there is decreased activity in the groups treated
with AuNS when compared with singular treatment with RT or AuNS conjugates (Figure 3.11).
Slow increase of the fluorescent intensity is observed overtime. These membrane potential
studies and metabolic seahorse results are congruent with findings from the ROS assays
showing no difference in subcellular localization of AuNSs. This further supports the notion that
physical dose enhancement, as evidenced by the effects of nAuNS in close proximity to the
nucleus, from local secondary electron showers is the major mechanism for radiosensitization.
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3.4 Conclusion
Efficacious treatment of cancer cells with radiation results from the death of individual
tumour cells following RT exposure. The benefits of RT as a treatment strategy, however, must
be weighed with the effects on normal tissues. The dose response curves for tumour control and
normal tissue complications make up the therapeutic index – the tumour response given a set
level of normal tissue toxicity.[122] The therapeutic index equates the two responses and allows
for a cost-benefit analysis of the new treatment relative to the standard. Radioprotectors and
radiosensitizers are compounds that can widen the therapeutic window and allow for better
tumour control, lower normal tissue complications, or both. On one hand, the ideal radioprotector
shifts the normal tissue complication response curve to widen the therapeutic window because
it permits tolerance of higher RT doses in the normal tissue. On the other hand, the ideal
radiosensitizer moves the tumour response curve such that either a lower RT inflicts a similar
level of control than a set RT dose, or more control is achieved with the comparative dose.
The efficiency of AuNP cellular internalization is determined by factors such size, shape,
hydrophobilcity/hydrophilicity, elasticity, surface charge and modification.[127] Clonogenic
survival studies in vitro demonstrated potent radiosensitization with 50nm particles following
irradiation with a 220 orthovoltage beam, congruent with studies suggesting 50 nm as the
optimum diameter for AuNP internalization.[97, 120] Nanoparticle size dependence of
radiosensitization could be a result of the secondary electrons yield with the larger number of
gold atoms increasing the photoelectric interaction cross-section. Conversely, more gold atoms
on the surface of the particle also attenuate the secondary electrons produced in the core of the
particle through self-absorption.[128] The data presented here distinguish the radiosensitivity
resulting from subcellular localization vs from quantity of AuNS uptake, particularly between the
sAuNS and nAuNS treatment groups in which particle uptake is similar. Although clonogenic
assay data is not available for the normal HPDE cells, we hypothesize that the AuNS, particularly
the nAuNS treatment, has differential effect on tumor cells given the selective internalization in
HPDE cells compared to the Panc-1 and MiaPaca-2 cells as previously described in Chapter II.
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RT damage to cells is orchestrated by the secondary charged particles and free radicals
produced, with DNA as the primary target. Among the cellular mechanisms we explore are
increased production of oxygen free radicals and generation of DNA DSBs. Irradiation of cells
laden with nAuNSs does not increase ROS production compared to accumulation with pAuNSs
or sAuNSs since oxidative stress is quantified at a whole-cell level rather than within individual
cellular compartments where these AuNSs differentially accumulated. However, nuclear
localization of AuNSs in irradiated cells resulted in increased DNA damage that correlated with
enhanced cell kill in clonogenic survival assays compared to the non-nuclear targeted AuNS
groups. Furthermore, these results also suggest that sublethal damage is actively repaired
following AuNS enhancement of radiation-induced DNA damage because a single dose of 4 Gy
causes more clonogenic cell kill than two fractions of 2 Gy each per the split dose assay. The
fact that measured ROS levels and mitochondrial function does not correlate with subcellular
localization of AuNSs highlights that the higher DNA DSB production by the nAuNSs and
subsequent cell kill reflect an underlying physical phenomenon incited by the proximity of the
nAuNSs to DNA.
In fact, this is further highlighted by the loss of the shoulder region in the clonogenic assay
curves for the nAuNS-treated group. This characteristic bending of the curve models the effect
of DNA repair between RT fractions at lower doses and disappears at higher doses, or with
higher quality (LET) RT. Given the results of the split-dose assay, the AuNSs here do not
significantly impair DNA repair. Therefore, proximity of AuNSs to the nucleus enhance the
response to a classically low LET radiation with an orthovoltage beam to mimic that of a higher
LET radiation source. High-LET radiations inflict greater biological effects per Gy than lo-LET
radiations. This is evident through an increase in RBE as LET increases up to roughly 100 keV/
m. All things considered, we demonstrate that AuNS-mediated radiosensitization is evident
across multiple types of RT, hence increasing the feasibility of clinical implementation with
photons or charged particle sources.
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3.5 Supporting information
1. Calculations for several factors discussed in this chapter are as follows:
•

Survival fraction for clonogenic assays

!" =

•

$%&'!"% )%* +, %-./
$%&'!"% )%* 012'*34'-56. 7*%82

Dose or radiation enhancement factor (DEF or REF)

$0"!"% =

•

$%&'!"% )%* +, %-./
$%&'!"% )%* 012'*34'-56. 7*%82

Recovery ratio
++%&'(%)'*% +&,-. =

!"/0*+1' 2,/'
!"3&(4%0,*(%'2 2,/'

2. DNA double strand break and intensity measurements from only identified cells requires
identification of total cell number prior to measurements.

Figure 3.12: Identification of primary objects for foci and intensity measurements.
Representative output for code in CellProfiler to identify and isolate cells for measurements.
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3. Representative cell cycle analysis images from flow cytometry.
A

B

24hrs post RT

Figure 3.13: Representative cell cycle histograms for MiaPaCa-2 cell line. (A) No RT and (B) 24
hours post-RT exposure. AuNS treatment groups are: blue (control – no AuNS), red (pAuNS),
gree (sAuNS) and purple (nAuNS).
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3.6 Materials and methods
Clonogenic assays
In vitro radiosensitization was evaluated for both Panc-1 and MiaPaCa-2 cell lines using
the classic clonogenic assay. Briefly, cells are plated and treated with AuNSs for 24 hrs prior to
RT (0, 2, 4 and 6 Gy) using XRAD 320 or the specified RT modality. The cells are harvested and
a known number of cells are re-plated in sextuplicate and allowed to grow in culture for 9-14 days
to allow for colony formation. The colonies are fixed and stained with 1% crystal violet in absolute
alcohol, washed extensively to remove excess dye, and imaged using a colony counter
(GelCount, Oxford Optronix). The numbers of surviving colonies with >50 cells/colony are
counted, survival curves plotted after normalizing for the cytotoxicity induced by AuNS alone,
and data are fitted to a linear-quadratic model. DEF was calculated as the ratio of the dose
resulting in 10% survival with radiation alone to that resulting in 10% survival with radiation plus
AuNS (normalized for AuNS cytotoxicity).

Mechanistic studies
Similar to uptake studies, cells are treated for 24 hrs according to assigned treatment
group prior to RT. ROS production was evaluated using the ROS-Glo kit (G8820, Promega). DSB
was evaluated by fixing cells and exposing them to anti-g-H2AX (Abcam ab11174) or anti-53BP1
(Abcam ab172580) primary antibodies after blocking with 5% BSA.overnight at 4°C. They are
then stained with secondary antibodies conjugated to Alexa Fluor 647 (Texas Red –
ThermoFisher Scientific A32723) or Alexa Fluor 488 (FITC – ThermoFisher Scientific A31852)
for 2 hours at room temperature, and lastly stained with DAPI (blue). Images are captured using
a fluorescence microscope (Leica DMI6000B, Leica Microsystems, Wetzlar, Germany) and foci
of immunofluorescence within the nuclei analyzed using SPOT software (Sterling Heights, MI,
USA). At least 50 nuclei were counted per experimental condition. Comet assay is performed
using the Trevigen CometAssay® reagent kit for single cell gel electrophoresis assay (Cat #
79

4250-050-0), and analyzed with the published OpenComet protocol and software.[129] Seahorse
assay is carried out using the Agilent Seahorse XF Analysis set-up courtesy of the Taniguchi Lab
at UT MD Anderson Cancer Center. Mitochondrial membrane potential is assessed using the
TMRE Mitochondrial Membrane Potential Assay Kit from Abcam (ab113852).
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Chapter IV: in vivo biodistibution and therapeutic efficacy
4.1 Abstract
Tumor localization of targeted radiosensitizers provide a mechanism for safer and
more effective cancer therapies. Moreover, the effects of their physiochemical properties on
the in vivo fate of these particles can result in better targeted therapies. Here, we evaluate
the in vivo distribution of the nanoparticles as a function of their surface chemistry. Mice
bearing subcutaneous human pancreatic tumors receive intravenous (tail vein) injections of
the nanoparticle formulations discussed in previous chapters (Figure 3.1). All particle
formulations are sterically stable in physiological concentrations of salt. Histological
evaluation of tissues with the highest uptake (liver and spleen), along with normal pancreas
tissue show no appreciable changes relative to normal, untreated tissue. In line with the in
vitro data, tumor growth delay studies reveal greatest radiosensitization effect with nucleartargeted gold nanoparticles. Furthermore, we test the efficacy of gold nanoparticle delivery
using thermosensitive liposomes to further enhance gold nanoparticle accumulation at the
tumor. Combined liposomal delivery with hyperthermia treatment results in greater
nanoparticle uptake at the core of the tumor, as well as improved tumor growth delay. These
results suggest that targeted nanoparticles can provide greater intracellular delivery of
therapeutic agents to the cancer cells within solid tumors than their non-targeted
counterparts, and that enhanced tumor uptake can be achieved through liposomal delivery.
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Figure 4.1: Graphical representation of chapter IV studies. Xenograft tumor models are
established to study AuNS biodistribution with and without liposomes, and therapeutic efficacy.
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4.2 Introduction
Medical applications of NPs depend on their ability to accumulate at a desired anatomical
site regardless of administration route. Several biological barriers limit site-specific NP
bioavailability, thereby hindering the ability to achieve therapeutic levels. These barriers include,
but are not limited to, opsonization followed by mononuclear phagocyte sequestration,
nonspecific biodistribution, blood flow limitations, pressure gradients, efflux pumps, clearance or
storage in reticuloendothelial system (RES) organs, and escape from endosomal or lysosomal
compartments.[1] Both passive accumulation via the enhanced permeability and retention (EPR)
effect, and active targeting rely on surface functionality of nanoparticles to determine the
biological distributions. The EPR effect established the increased accumulation of
macromolecules via extravasation through fenestrations in blood vessels present in tumors.[2]
However, the limitations of the EPR effect, such as unpredictable drug retention and
heterogenous vascular permeability, emphasize the need for active targeting through innovative
design of decorated particles.[3]
The discovery of the enhanced permeability and retention (EPR) effect fundamentally
transformed understanding of how therapeutic and contrast agents accumulated within the tumor
microenvironment. This prompted the development of nanoparticle-based therapeutics in cancer
treatment. While larger molecules diffuse randomly, nanomaterials can extravasate into tumors
via leaky vasculature. However, the immature and leaky tumor vessels leads to heterogeneous
vascular perfusion within tumors. The invasive periphery of the tumor typically contains the
highest microvascular density while the tumor core is underperfused and thus, underexposed to
intravenously delivered agents. In addition to the physiological barriers already imposed by the
interstitial matrix (glycosaminoglycans, collagen, proteoglycans), the dense stromal component
(desmoplasia) of pancreatic cancer further hinders the delivery of nutrients, oxygen and drugs.
The consequent hostile microenvironment (low pH, low pO2) of the tumor core harbors the most
aggressive tumor cells with the greatest potential to regenerate if they survive cytotoxic
treatment.
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We examine the passive cellular uptake and active nuclear targeting in Chapter II, and
the in vitro effects of combined RT and AuNS treatment in Chapter III. Here, we investigate the
in vivo radiosensitization potential of AuNSs in pancreatic cancer models, as well as the effect of
active nuclear targeting combined with RT. Additionally, we develop an innovatively designed
delivery system to penetrate the physio-chemical barriers of pancreatic cancer using
thermosensitive liposomes (TSLs). TSLs accumulate passively in the tumor via the EPR effect,
and upon an external trigger (hyperthermia), TSLs release their payload.
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4.3 Results and discussion
Biodistribution and in vivo toxicity studies
We perform in vivo biodistribution studies in immunodeficient nude mice harboring
xenografts of Panc-1 and MiaPaCa-2 cells. 24 hours following intravenous administration of
pAuNS, sAuNS or nAuNS, normal organs (brain, lung, heart, liver, spleen, kidney, intestine and
muscle), tumors and blood were collected for quantitative analysis of gold content using ICP-MS
(Figure 3.2). As expected, the liver and spleen contain the highest amounts of gold. AuNS
accumulation in the tumor is relatively similar across the three conjugate groups, and slightly
higher quantities of gold are present with the AuNS conjugate group than the non-targeted
groups. Blood levels demonstrate that AuNSs remain in circulation, albeit at very low
concentrations. Normal pancreas tissue contains minimal gold content. Of note, no appreciable
changes in the behavior, body weight, appearance or food/water intake of mice was noted
following AuNS administration.
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Figure 4.2: AuNS biodistribution studies. In vivo AuNS biodistribution 24 hours post particle
administration in (A) Panc-1 cells and (B) MiaPaCa-2 tumor models. (C) Normal pancreas
tissue uptake of AuNS. (D) AuNS biodistribution at 48 hours post particle administration.
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Although mice with Panc-1 tumors received twice the concentration of AuNSs, the tumor
gold content is similar for both tumors. This may reflect the heterogeneity in vascular and tumor
microenvironment present between the two tumor types. Looking forward to liposomal studies,
we evaluate the in vivo biodistribution of AuNSs in harboring MiaPaCa-2 tumors 48 hours
following AuNS treatment. Similar to the earlier time point, the liver accumulation is high relative
to other tissues. In fact, tumor uptake is slightly decreased from the 24 hour time point. However,
this decrease did not affect the radiosensitzation effect as we discuss in the next section.
Interestingly, the quantity of gold decreases in the spleen at 48 hours while the kidney content
increases. This perhaps reflects renal clearance of the AuNSs overtime. In addition to obtain
tissues for qualitative assessment of toxicity.
RES organs (liver and spleen) demonstrate considerable AuNS uptake and clearance in
spite of the small size, or particle surface functionalization by PEGylation or peptide conjugation.
Analysis of hematoxylin and eosin stain of normal pancreas, tumor and tissues with the highest
AuNS uptake (liver and spleen) qualitatively show no effect of AuNS treatment in mice. (Figure
3.3) Taking this a step further, we assess the effect AuNS exposure has on immune activation
and coagulation in donor human blood samples. Complement activation assays reveal no
difference in activation of the classical pathway, however, there is a differential effect with sAuNS
treatment activatng the mannose-lechitin pathway and nAuNS treatment activating the
alternaltive pathway to a greater extent than other treatment groups (p<0.01). (Figure 3.3)
Evaluation of clotting factors in human donor samples also demonstrate no effect of AuNS
treatment on prothrombin time (PT), international normalized ratio (INR), partial thromboplastin
time (PTT) and thrombin time (TT). Taken together, this results reinforce the biocompatibility of
the AuNSs designed.
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Figure 4.3:. In vivo AuNS toxicity, (A) H&E stain of the liver, spleen, normal pancreas and
tumor qualitatively indicate no difference in control and AuNS-treated groups. (B) Complement
activation assays with donor human serum reveal non-statistically significant relative activation
levels for the classical pathway, and a differential activation of the mannose-lechitin binding
pathway for sAuNS and the alternative pathway for nAuNS. ((C) Measurements of PT, INR,
PTT and TT in human blood donor samples reveal no effects of AuNS treatment.
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Radiosensitization with AuNS
We assess the therapeutic potential of AuNSs treatment in combination with RT using
tumor growth delay (TGD) assays. Preliminary studies informed our decisions on the number of
mice per group. For the Panc-1 xenograft models, we treat with a single dose of 6 Gy using 250
kVp orthovoltage x-rays 24 hrs after AuNS treatment (5 µg/g) – Figure 3.4. We observe delayed
tumor regrowth in the non-targeted pAuNS + RT group; this delay is even more pronounced for
the nAuNS + RT group. It is noteworthy that half the mice in the nAuNS + RT group had complete
tumor regression. This suggests a dose depended mechanism as determined by the split dose
assau in chapter III. Moving forward, a single RT dose of 8 Gy is used for subsequent studies.
Based on the biodistribution studies, we also included additional groups with a 48 hr delay
between AuNS administration and RT in the MiaPaCa-2 tumor model.
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Figure 4.4: Panc-1 TDG studies. (A) Preliminary tumor growth delay to determine sample size
for future experiments. (B) Individual tumor growth delay curves for each treatment group with
statistically significant differences relative to the control group: p < 0.01 for both pAuNS + RT
and sAuNS + RT groups, and p<0.0001 for nAuNS + RT groups relative to RT only, and
nAuNS only treatment group. Also, p<0.0001 for nAuNS + RT compared to pAuNS + RT and
sAuNS + RT.
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In the MiaPaCa-2 xenograft models, we use half the AuNS concentration based on in
vitro studies and observe complete tumor regression in all mice for the nAuNS + RT treatment
group when the sequencing interval is 24 hr, and all but one mouse when the sequencing interval
is 48 hr. The tumor regrowth delay is significantly longer than that of the control, RT only, pAuNS
+ RT and sAuNS + RT groups (p<0.0001) (Figure 3.5). Survival curves demonstrate improved
survival in the AuNS + RT treatment groups when compared to control or RT only treatment
groups with p = 0.002 and p<0.0001 by log-rank (Mantel-Cox) test, respectively.
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Figure 4.5: In vivo MiaPaCa-2 tumor growth delay and survival studies. (A) Individual normalized tumor
volumes for each treatment group with statistically significant differences relative to the RT only group:
p<0.01 for both pAuNS + RT and sAuNS + RT groups, and p<0.0001 for nAuNS + RT groups relative to
RT only. Also, p<0.0001 for nAuNS + RT compared to pAuNS + RT and sAuNS + RT. Kaplan-Meier
survival curves of mice when RT was given 24 hrs (B) and 48 hrs (C) after AuNS administration. In both
figures, AuNS + RT treatment resulted in statistically significantly better survival than control or RT only
groups with p = 0.002 and p<0.0001 by log-rank (Mantel-Cox) test, respectively.
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Liposomal design and kinetics
Untargeted particle use for radiosensitization generally requires large intratumoural
accumulation of gold to achieve the desired effect. We are able to achieve local tumor control
with nuclear-targeted AuNPs as demonstrated in the previous section. To further maximize the
uptake of AuNSs in the tumour, especially at the under-perfused tumour core, we encapsulate
the AuNSs in liposomes. Liposomes are an archetypal nanoparticle system that are a
cornerstone for modern drug delivery initially discovered in the 1960’s.[130] Liposomes are
spherical structures made up a phospholipid bilayer membrane capable of encapsulating
hydrophobic or hydrophobic agents. Liposomes are desirable vesicles for delivery because they
are inert and weakly immunogenic. We utilize a design strategy to encapsulate the AuNSs in
liposomes that are triggered by hyperthermia (HT) to release the AuNSs once in the tumor
microenvironment. The liposomes are characterized similarly to the AuNSs in Chapter II (Figure
3.6). The liposome design process is illustrated in the supporting information, and
characterization described here.
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Figure 4.6: TSL characterization and release kinetics. (A) DLS and (B) zeta potential
measurements for the 2 liposomal formulations, reveling similar sizes and negative surface
charge as expected. (C) Release kinetics highlighting release of AuNSs from TSLs following
exposure to a specific temperature range (40 – 42oC). For each time point, samples are tested
in triplicate.
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Biodistribution with liposomes
The bigger size of liposomes relative to the AuNSs allows for encapsulation of a large
number of nanospheres within the bilayer or the cavity, and PEGylation ensures stability and
longer circulation times. A 2010 study found higher levels of gold internalization when smaller
AuNPs, 1.4 nm in diameter, were delivered via liposomes.[131] We hypothesize that externally
triggered release of the AuNSs from the liposomes using hyperthermia (HT) results in deep tumor
penetration by the AuNSs. We assess the gold content using biodistribution studies in xenografts
established with both Panc-1 (at 4 hours post treatment) and MiaPaCa-2 (at 24 hours post
treatment) cells (Figure 4.7). These studies reveal much higher uptake of liposomes by the liver,
consistent with the observation that larger nanoparticles are hepatically cleared. Additionally,
tumors appear hyperemic following HT treatment for 5 min. Tumors are sectioned to obtain
tissues from the core and periphery. Gold content reveals similar levels of gold in the periphery
sections, while HT treatment increases gold quantified in the tumor core. This difference is not
statistically significantly different between the nAuNS + HT vs nLipo + HT groups.
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96

Radiosensitization with liposomes
Several studies and clinical trials demonstrate the utility of HT in cancer treatment. (5, 8)
As such we expect improved tumor growth delay and survival in the group treated with
combination HT + RT + AuNSs relative to those treated with a singular or double agent treatment.
As expected, combination of nAuNS and RT results in complete tumor regression in a majority
of the mice in the nAuNS + RT and nAuNS + HT + RT groups. This observation is independent
of HT treatment. Furthermore, nLipo + HT + RT treatment also results in complete tumor
regression. Notably, nLipo + HT + RT results in an improved therapeutic effect compared to HT
alone or HT + RT. This implies that the presence of AuNSs, even when encapsulated in
liposomes, still results in radiosensitization and improved local tumor control. This effect is more
pronounced when AuNS is released from the liposomes, but present, nonetheless.
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Figure 4.8: In vivo tumor growth delay with TSLs. Individual normalized tumor volumes for each
treatment group with statistically significant differences relative to the HT only group: p<0.0001 for both
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4.4 Conclusion
In order to successfully amass in the desired biological target, NPs must remain in
circulation in concentrations high enough to localize in the tumours. We demonstrate that the
AuNSs designed here accumulate in the tumour without cell-specific receptor targeting.
Moreover, toxicity studies reveal no measurable adverse effects of AuNS in the tissues
examined. These results affirm the potential use of the AuNSs to enhance RT effects in the
tumour while simultaneously minimizing the toxicity to normal tissues. Similar to the split dose
assay in Chapter III, non-curative doses of radiation combined with nAuNS in vivo resulted in
complete tumor regression in >90% tumors. Comparable in vivo radiosensitization effects in two
independent tumor xenograft models suggests that passive targeting may be sufficient for tumor
uptake. Indeed, active targeting has not shown demonstrably larger accumulation of
nanoparticles in tumors.[132] However, passive targeting relies on the enhanced permeability
and retention effect that tends to be heterogeneous, especially for larger tumors and tumors
exhibiting differing levels of vascularity.[133, 134]
Despite the proven clinical utility of the EPR effect, there are several limitations due to
the difficulty to control the tumour uptake which can ultimately contribute to multiple drug
resistance. (107) Liposomes loaded with drug cargo were first reported in 1973, however, the in
vivo delivery efficiency was hampered by interactions by macrophages and serum complement
compounds which caused premature drug release in the blood.[135, 136] This incited the design
of liposomes with longer circulation times and reduced toxicity.[137, 138] Consequently, several
liposome-encapsulated drugs received FDA approval, such as doxorubicin (Doxil) in 1995 for
treatment of Kaposi’s sarcoma and albumin-bound paclitaxel (Abraxane) in 2005 for metastatic
breast cancer.[139, 140] These formulations have since received approval for treatment of
several ailments, and continue to be investigated along with other drugs for additional clinical
applications.[141] Effective liposomal-based therapy requires encapsulation of the relevant drug,
avoidance of the mononuclear phagocyte system, accumulation at the desired target and
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important, effective release of high enough levels of the payload to cause a therapeutic
effect.[142]
Once liposomes accumulate in the tumour, drug is released passively over long-periods
of time or following natural degradation of the lipid bilayer. This passive release, however, can
result in sub-optimal release kinetics causing diminished therapeutic gains.[143-146] Therefore,
studies explored development of liposomal delivery systems capable of releasing the payload in
following a specific stimulus. This triggered release mechanism optimizes time, location and drug
concentration kinetics at the target site. Several groups looked into stimuli-responsive liposomal
formulations such as temperature, pH, ultrasound or photo-sensitivity triggers for release.[141,
147-150] Temperature, or thermos-, sensitive liponses are closest to clinical application with
several clinical trials.[150, 151] We employ TSLs combined with HT to enhance AuNS uptake at
the tumour core, thus improved radiosensitization. Mild HT triggers the release of the AuNSs
locally in the tumour microenvironment, enabling the small AuNSs to escape clearance in the
blood stream. Once in the TME, tumour cells can internalize the AuNSs and allow for nuclear
uptake for the targeted particles.
Besides, HT has been used therapeutically for many years, even with radiation and
chemotherapy in cancer treatment.[152] HT treatment results in increased vascular permeability
and blood flow to the tumour, features desirable in drug delivery. Additionally, HT can improve
drug accumulation to hypoxic regions of tumour which are normally resistant to therapy due to
the low perfusion by increasing blood flow and drug plus oxygen delivery. Regional HT is
particularly important here for the liposomes and combined RT treatment because it results in
increased AuNS accumulation and release in the target tumour periphery and core, thereby
enhancing the therapeutic index. This enables greater local tumor control while reducing the
potential off-target effects, the overall aim of this thesis.
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4.5 Supporting information
•

Tumor volume calculations based uponcaliper measurements of long and short axis tumor
dimensions
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Liposome synthesis employing a thin film hydration method. AuNSs in PBS are added to
the lipids to form multilamellar liposomes. The particles are then extruded multiple times
through variety of filters to obtain the desired size.

Figure 4.9: TSL synthesis schematic. Aqueous AuNS solution is added to thin film of lipids and
heated to create an emulsion to allow multilamellar liposome formation. This emulsion is then
allowed to cool down and extruded to obtain desired size of liposomes.
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4.6 Materials and methods
Biodistribution
Male athymic Swiss nu/nu mice 6-8 weeks old are purchased, maintained, and handled
using protocols approved by Institutional Animal Care and Use Committee (IACUC) at M.D.
Anderson Cancer Center. Subcutaneous xenografts are generated by injection of 1-2 x 106 Panc1 or MiaPaCa-2 cells into the right thighs of mice. When tumors grow to ~7mm in diameter, they
are administered intravenous AuNS (5 µg/g) while anesthetized using isoflurane. Twenty-four
hrs later, mice are euthanized and the blood, tumor, and normal organs are harvested, stored in
pre-weighed glass vials and frozen at -80℃ until further processing. Frozen samples are
lyophilized for 2-7 days to ensure complete dehydration of tissues before dry weights are
measured. Afterwards, 1 mL of aqua regia is added to each vial for digestion of tissues with slight
heating for denser tissues like liver. 1% nitric acid solution is added to digested samples to bring
the final volume to 10 mL for each sample. This solution is filtered through a 0.25 µm microfilter
prior to ICP-MS analysis with standards measured in parallel. The amount of gold per unit dry
weight of tissues was calculated.

Tumor growth delay
Subcutaneous pancreatic cancer xenografts of both cell lines (as noted above) are used
to assess tumor growth delay. Mice are randomly assigned to treatment groups of RT alone,
AuNS alone, RT + AuNS or no treatment. Animals treated with combination therapy receive
intravenous administration of 100 µL of 10 OD (optical density) of AuNS 24 hrs prior to RT.
Control mice and those receiving RT alone receive 100 µL of PBS. RT is administered using an
orthovoltage unit (Philips RT-250, 250 kVp beam with a Cu-filter) equipped with a cone applicator
to focus radiation toward the tumor target while the mice are anesthetized with an intraperitoneal
injection of 100 µL of 5% ketamine and 10% xylazine in PBS. Tumors are measured 2-3 times a
week using digital calipers and tumor volumes were calculated as ½ x (long axis diameter) x
(short axis diameter)2. Tumor volumes are normalized to the initial tumor volume for each mouse,
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averaged across groups and plotted over time. Animals are euthanized when tumor diameter in
one dimension exceeded 2 cm, or animals lost greater than 20% body weight, were unable to
feed by themselves, or survived past 365 days.

TSL design and synthesis
The themosensitive liposomes are formulated by a lipid mixture of dipalmitoyl
phosphatidylcholine

(DPPC),

1-myristoyl-2-palmitoyl

phosphatidylcholine

(MPPC),

and

distearoyl phosphatidyl-ethanolamine-polyethylene glycol 2000 (DSPE-PEG-2000) in a molar
ratio of 90:10:4 employing a thin film hydration method [27]. 1ml PBS containing 5-nm AuNSs is
used to hydrate the thin film of lipids at a transition temperature of 65oC for 1 hr to allow the
transfer of AuNSs to the core aqueous region of the liposome. The suspended TSLs are extruded
through 400 nm, 200 nm then 100 nm pore filter membranes. Free AuNSs are removed using
1000 kDa molecular weight cut-off vivaspin tubes.
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Chapter V: Summary and conclusion
5.1 Significance
Rapid developments in the field of cancer nanotechnology have facilitated the creation of
numerous types of nanoparticles with varying sizes, shapes and targeting properties. This has
fueled the pursuit of meaningful clinical applications for cancer therapy while simultaneously
minimizing toxicities to normal tissues. These studies report the enhancement of the therapeutic
effects of RT in pancreatic tumor cells when used in conjunction with sub-cellularly targeted
AuNPs. The combination of nanoparticle localization and the targeted delivery of radiation both
augment the radiation effects on the tumor, and reduce the side effects to normal cells. Although
these studies are performed in the context of pancreatic cancer, these particles can be used in
other solid tumors as they are not purposely targeted to a cell-specific receptor.

Figure 5: Chapter V graphical summary. Nuclear-targeted gold nanoparticles presented here
achieve their therapeutic potential primarily due to their proximity to cancer cell DNA.
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5.2 Summary

Cancer is the second leading of mortality in the US. Pancreatic cancer (PC), specifically,
is the third leading cause of cancer deaths and predicted to become the second by 2025.[1, 153]
Also referred to as pancreatic ductal adenocarcinoma (PDAC), PC is one the most aggressive
malignancies with 5-year survival rates of less than 10%. Poor prognosis is attributed to the
complicated and multifactorial nature of the disease with limited treatment options. Surgical
resection presents the only real chance for a cure, unfortunately, roughly 15 – 20% of individuals
present with resectable disease and long-term survival still low in these cases.[154, 155] An
autopsy series highlighted the need for localized therapy by noting 30% of all pancreatic patients
die from locally destructive disease regardless of clinical stage at presentation, treatment history
or histopathological features.[33] Radiation (RT) offers one of the few truly localized clinical
treatments, but curative doses are not clinically achievable due to the toxicities to healthy
surrounding tissues. Therefore, innovative RT strategies become promising options in
combination with targeted nanotechnology to combat pancreatic cancer in a directed manner.

The overarching goal of this thesis is to radiosensitize pancreatic cancers by designing
nuclear-targeted gold nanoparticles packed into thermally activated liposomes that release their
payload upon external stimulation. Radioresistance is a major mechanism of tumor progression
that has previously hindered progress in the treatment of aggressive cancers. [1-9] Delivering
higher doses of radiation to the gross tumor to overcome radiation resistance has historically
been challenging due to the limited radiation tolerance of the surrounding organs. Sequestering
gold nanoparticles (AuNPs) within tumors to amplify radiation-induced secondary electron
showers has been investigated as a means to escalate radiation dose in the vicinity of the
nanoparticle at micron/nanometer ranges, thus confining the higher dose to the tumor and
sparing surrounding tissues.[10-39] Maximizing this radiosensitization requires (i) deep
penetration of these nanoparticles inside tumors at the tissue level, and (ii) accumulation near or
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within the nucleus at the cellular level – both of which still remain major challenges. This work
surmounts these challenges by enhancing accumulation of gold deep within the radioresistant
core using thermosensitive liposomes to deliver nuclear-targeted gold nanoparticles.

A fundamental objective for drug delivery is targeted release of a drug at a desired rate
and concentration. Nanoparticles are of particular interest because they can selectively
accumulate at a desired site, either through the EPR effect or active targeting. Factors that play
a role in the clearance and accumulation of NPs include size, shape, charge and functionalization
status. Several groups have investigated the effects of NP size on biodistribution and found that
size determines clearance of NPs from the blood stream with NPs > 5 nm excreted via renal
clearance while particles > 100 nm are cleared through spleen and liver sequestration.[156-158]
NPs with sizes falling in the range of 5 – 100 nm showed increased circulation times, and
therefore, systemic clearance and tissue accumulation for these particles is dependent on
additional factors such as shape and surface chemistry.[159, 160] NP shape determines in vivo
fate by affecting the circulation, margination ability and binding affinity in favor of non-spherical
NPs.[161, 162] Active targeting through functionalization of NPs with targeting moieties further
underscores the versatility of NPs in their potential applications. NPs decorated with peptides or
antibodies are readily taken up by cells via receptor-mediated endocytosis, accumulating within
endosomal vesicles. Targeted NPs can also be functionalized for sub-cellular targeting to enable
more specific compartmentalization.[163, 164]

Irradiation of tumours laden with high atomic number (Z) materials such as gold results
in radiation dose enhancement via increased secondary electron production from nanoparticleradiation interactions.[75, 115, 116] The augmented density of ionization localized near or at the
surface of the AuNPs leads to enhanced probability of lethal damage to cells containing the
materials by transiently increasing the radiation-interaction cross section in the target tissue. A
seminal study 40 years ago demonstrated the radiosensitization potential of iodine in cultured
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cells.[117] This was later validated in vivo when injection of iodine into tumors followed by
radiation resulted in roughly 80% suppression of tumor growth in mouse models.[118] Gold has
been pursued as a radiosensitizer given its higher Z than iodine (Au, Z = 70 vs. I, Z = 53) and
biocompatibility.[75]

Studies investigating the concentrations of high Z materials with radiation found that in
order to achieve radiosensitization, higher concentrations of iodine and gold (~5mg/g) were
required.[75, 119] When the gold nanoparticles (AuNPs) were internalized in vitro, however,
radiosensitization effects were observed at concentrations as low as 10-6 mg/g.[115] These
results are consistent with previously published work demonstrating in vitro sensitization with
AuNP concentrations of ~10-3 mg/g at both kilovoltage (kV) and megavoltage (MV) energies of
radiation.[120] Based on these observations, it is possible to achieve radiosensitization effects
at considerably lower concentrations, given intra-cellular or sub-cellular accumulation of AuNPs.

In this thesis, nuclear localization of gold nanoparticles via surface decoration with NLS
peptides potently increases radiosensitization in pancreatic cancer models in vitro via an
increase in oxidative stress and DNA damage. Importantly, these findings were reproduced in
vivo when nAuNSs were systemically administered at concentrations (5 mg/Kg) that are readily
achievable in a clinical setting. To date, efficient drug delivery via active targeting of AuNSs to
cancer cells has usually terminated with cellular internalization rather than with nuclear
localization, despite the nucleus housing DNA, the critical driver of radiation damage to cells.
Furthermore, given the very short latency and limited spatial diffusion capability of in-situ
radiation-triggered ROS, localizing AuNSs in close proximity to DNA is a desirable attribute of
such drug delivery strategies. Nonetheless, to our knowledge, most prior work with NLS
decoration has been performed in vitro and not in vivo making the therapeutic efficacy seen in
our study especially noteworthy.[165] We surmise that this is partly because, unlike gene therapy
that requires nuclear access of the delivered construct, complete nuclear uptake of AuNSs is not
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required for radiosensitization; even cytoplasmic accumulation increases radiosensitization while
nuclear uptake enhanced this even further. This transmembrane transport of our AuNSs is aided
significantly, however, by their small size (~5 nm) that allows faster diffusion through the nuclear
pore complex comprised of dynamically fluctuating phenylalanine-glycine nucleoporins and their
decoration with NLS that binds the importin α subunit of the importin α-β heterodimer that shuttles
cargo through the nuclear pore complex.[166, 167] It is noteworthy that TAT-peptide derived NLS
also serves as an aid to cell membrane penetration.[168] It is likely that greater endosomal
escape (possibly via the proton sponge effect of custom peptides) or use of other cell penetrating
peptides may further increase nuclear accumulation for even greater radiosensitization.

Nonetheless, the complete eradication of tumors in the nAuNS + RT group, further
confirmed in the liposomal HT groups, in a majority of mice over a very long follow-up period
speak to the robustness of this approach, and the potential for advancement of this strategy to
the clinic where other gold nanoparticle formulations have so far been unsuccessful. These
results extend the large body of literature confirming that loading tumors with high atomic number
(Z) materials such as gold results in radiation dose enhancement via increased secondary
electron production.[75, 115, 116] A higher density of ionization localized near or at the surface
of the high-Z element accounts for the large interaction cross-section and sequestering the highZ element in the nucleus can spatially confine the ionization closer to DNA, the predominant
target of radiation injury.

The successful application of nanoparticles in biomedical applications depends upon
selective accumulation at the site of interest and the ability to overcome biological barriers.
Ongoing research is required to elucidate the correlation between nanoparticle physiochemical
features and the pharmacological/biological kinetics. Specific to this thesis, additional studies
with orthotopic tumor models, clinically adaptation of AuNS treatment, and hyperthermia delivery.
For example, we intended to utilize high intensity focused ultrasound (HIFU) to deliver HT
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treatment since future clinical application would greatly benefit from localized treatment at the
tumor. The superficial xenograft tumor models here are amenable to the method used, but deepseated tumors would require a non-invasive and targeted form of delivery such as HIFU or MRIguided FUS. Perhaps in this case, we can better demonstrate the additive or synergistic effect
of combining HT-triggered release of radiosensitizing AuNSs with radiation. Ultimately, optimal
clinical utility of HT in the setting of nanoparticle-mediated radiosensitization will require definition
of different techniques that successful in different clinical scenarios in order to integrate HT into
clinical practice.

In summary, radiation combined with nuclear-targeted gold nanoparticles radiation
delivered with or without liposomes are proven to improve the effects of radiotherapy in a single
dose setting for pancreatic xenograft models. Given that these nanoparticles are not targeted to
a specific tumor type, this system could be envisaged as a turn-class key technique for local
enhancement of effects of radiation therapy. Furthermore, these AuNSs or liposomes could be
dually targeted with a tumor specific marker or delivered as a therapeutic in a targeted manner.
Moreover, there is a differential uptake in normal tissues because uptake is dependent on
abnormalities in the tumor microvasculature. These combined treatments could be utilized to
deliver a higher dose to enhance tumor control. In the case of adequate tumor control, this
method can serve to decrease the total dose of radiation delivered, which could alleviate normal
tissue toxicity that usually limit treatment. Lastly, given that the effects are dose dependent, this
mechanism would perhaps benefit from the high-precision stereotactic radiation treatments
increasingly implemented in clinic for the treatment of patients. The multidisciplinary nature of
this concept requiring collaboration in scientific disciplines such as chemistry, nanotechnology,
pharmacology, bioengineering, imaging and radiation physics, and tumor and radiation biology
underscores the potential to advance radiation therapy.
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Appendix: Common methods
Nanoparticle synthesis and conjugation
AuNS synthesis
Gold nanospheres (AuNSs) were synthesized using a bottom-up approach through
reduction of hydrogen tetracholoauric acid (HAuCl4 – MW 339.785 g/mol) with sodium
borohydride (NaBH4 – MW 37.83 g/mol) through a modified protocol used by Martin et al.[113]
Upon addition of the HAuCl4, the solution turned a bright orange color as a quick measure of the
size of nanoparticles formed. Some of the solution was removed for characterization of newly
formed AuNSs prior to conjugation procedures.

AuNS conjugation
Methoxy-polyethylene

glycol

2000

thiol

(mPEG-2K-SH)

and

bifunctional

thiol

polyethylene glycol 2000-N-hydroxylsuccinimide (NH2-PEG-2K-SH) were purchased from
NanoCS and stored at -20℃. PEG solutions were added to AuNS solutions at 4℃ and the
reactions allowed to occur for 24 – 48 hours. Following PEGylation, AuNSs were centrifuged for
30 minutes at 3500xg through 100 kDa filters in order to concentrate the nanoparticles and
remove unbound reactants. Non-targeted AuNSs groups consisted of particles with the
monofunctional mPEG for the pegylated group (pAuNS), and the bifunctional amine-PEG-thiol
which was further conjugated to a peptide of similar molecular weight to the nuclear localization
sequence peptide used for targeting (sAuNS). The peptide conjugation was accomplished using
carbodiimide crosslinker chemistry with EDC (1-Ethyle-3-[3-dimethylaminopropyl]carbodiimide)
and sulfo-NHS (N-hydroxysuccinimide) to attached the primary amine on the bifunctional PEG
molecule to the carboxylic acid (-COOH) group on the peptides. Each peptide had a singular COOH group, ensuring a directional conjugation. Nuclear-targeting was achieved via conjugation
of an HIV-Tat 1 derived peptide (Sigma-Aldrich) for the nAuNS group. Final AuNS construct
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solutions were rinsed with PBS and further centrifuged for additional purification and
concentration, then characterized as described below and stored at 4℃ until use.

Peptide quantification
To further assess successful conjugation of the peptides to the AuNSs, the amount of
protein on the surface of the AuNSs was estimated using a colorimetric assay. Briefly, samples
of bare AuNSs, pAuNS, sAuNS and nAuNS with equal absorbance at 562 nm in a UV-clear
bottom 96-well plate (Corning 3635) were reacted with bicinchoninic acid (ThermoFisher
MicroBCA Protein Assay Kit 23235) for 2 hours at 37 then read at 562 nm using a
spectrophotometer (BioTek Cytation 5). The differences observed in 562 nm absorbances in the
groups, specifically for the sAuNS and nAuNS groups, was assumed to result from the presence
of peptides present at the surface of the AuNS.

Characterization
Absorbance
Surface plasmon resonance creates an extinction spectrum dependent on the size, shape
and aggregation status of AuNPs. Several factors such as surface charge (6), inter-particle
distance (7, 8), chemical interactions at the particle surface (5), and medium dielectric properties
(2-4) affect the position of the plasmon resonance. Therefore, Ultraviolet-visible (UV-vis)
spectroscopy provides fast and real-time monitoring of the AuNPs during synthesis because it
provides information on nanoparticle size, aggregation and concentration. (Amendola ns
Meneghetti, J Phys Chem 2009) In present work, UV-vis spectra were obtained and recorded
using a Cary 100 Bio UV-Vis spectrometer to obtain extinction spectra on AuNSs using a 1 cm
path length quartz cuvette and AuNP solutions diluted roughly 5-10 times the stock solution in
Milli-Q water.
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Particle size and surface charge
One of the few methods used for determining the size of nanoparticles in solution is
dynamic light scattering (DLS) by measuring the hydrodynamic size. In this technique, a
monochromatic laser illuminates the nanoparticle solution, and a photon detector at a fixed or
variable angle registers the scattering intensity. Nanoparticle solutions commonly comprise of a
distribution of sizes due to the imperfections in synthesis and natural conformational variances
in the vast number of atoms involved. The polydispersity index (PI) is the metric equivalent to the
relative variance of size distribution. DLS measurements were performed using a Malvern
Zetasizer Nano ZS operating at 15 mW of a solid-state laser (λ = 670 nm), using a scattering of
90°. For each synthesis, the same dilution used for UV-vis was used for size and charge analysis
within an optical density range between 0.3 to 0.5 units.

In vitro studies
Cell culture
Deidentified Panc-1 and MiaPaCa-2 pancreatic cancer cell lines purchased from the
American Type Culture Collection (Manassas, VA, US) were cultured in complete growth medium
(DMEM/F-12 supplemented with 10% FBS, 100 units/mL penicillin and 100 units/mL
streptomycin). HPDE (human pancreatic ductal epithelial) cells were cultured in Keratinocyte
SFM (serum-free medium) supplemented with 25 µg EGF (human recombinant epithelial growth
factor) and 25 mg BPE (bovine pituitary extract). Cells were passaged once or twice weekly for
maintenance, depending on growth rate and confluence. General passage protocol includes
rinsing with phosphate buffered saline (PBS – HyClone SH30256), detachment using 0.05% or
.025% trypsin-EDTA (ThermoFisher) with incubation for 5-20 min, neutralization using growth
medium plus trypsin inhibitor for HPDE cells, centrifugation and finally resuspension to desired
cell concentration. Cell concentrations were determined using the automated BioRad TC10™
cell counter. Cell culture incubators were maintained at 37℃, 5% CO and 90% - 95% humidity.
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All tissue culture plates and flasks were labelled with cell line name, passage number, date of
passage and initials of experimenter.

Cellular gold content
Following a 24 hour treatment period, cells washed thrice with PBS, trypsinized with
0.05% or 0.25%Trypsin in EDTA solution (Invitrogen), and cell suspensions prepared for
inductively coupled plasma mass-spectrometry (ICP-MS). A minimum of 500,000 cells per
experimental condition are suspended in 50 µL of PBS and 1 mL of Aqua Regia solution (1:3
HNO3:HCl) added to digest the samples. These suspensions are kept at room temperature for
2 – 3 days. After complete digestion, the final volume for each sample was brought to 10 mL by
adding 1% Aqua Regia solution, and each sample run through an ICP-MS instrument (PerkinElmer Inc.) to quantify gold content. A similar procedure is carried out for fractionated samples,
and amount of protein used to normalize gold content instead of cell count.

Imaging
Light microscopy, fluorescencent and darkfield imaging is executed using the Leica
DMI8000B, Leica Microsystems, Wetzlar, Germany. For TEM analysis, samples aree fixed with
a solution containing 3% glutaraldehyde plus 2% paraformaldehyde in 0.1 M cacodylate buffer,
pH 7.3, then washed in 0.1 M sodium cacodylate buffer and treated with 0.1% Millipore-filtered
cacodylate buffered tannic acid, postfixed with 1% buffered osmium, and stained en bloc with
1% Millipore-filtered uranyl acetate. The samples are dehydrated in increasing concentrations of
ethanol, infiltrated, and embedded in LX-112 medium. The samples are polymerized in a 60 C
oven for approximately 3 days. Ultrathin sections are cut in a Leica Ultracut microtome (Leica,
Deerfield, IL), stained with uranyl acetate and lead citrate in a Leica EM Stainer, and examined
in a JEM 1010 transmission electron microscope (JEOL, USA, Inc., Peabody, MA) at an
accelerating voltage of 80 kV. Digital images are obtained using AMT Imaging System
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(Advanced Microscopy Techniques Corp, Danvers, MA).This work was possible with the CCSG
grant NIH P30CA016672 to the High Resolution Electron Microscopy Facility.

Radiosensitization assays
In vitro radiosensitization was evaluated for both Panc-1 and MiaPaCa-2 cell lines using
the classic clonogenic assay. Briefly, cells are plated and treated with AuNSs for 24 hrs prior to
RT (0, 2, 4 and 6 Gy) using XRAD 320. The cells were harvested and a known number of cells
were re-plated in sextuplicate and allowed to grow in culture for 9-14 days to allow for colony
formation. The colonies were fixed and stained with 1% crystal violet in absolute alcohol, washed
extensively to remove excess dye, and imaged using a colony counter (GelCount, Oxford
Optronix). The numbers of surviving colonies with >50 cells/colony were counted, survival curves
were plotted after normalizing for the cytotoxicity induced by AuNS alone, and data were fitted to
a linear-quadratic model. DEF was calculated as the ratio of the dose resulting in 10% survival
with radiation alone to that resulting in 10% survival with radiation plus AuNS (normalized for
AuNS cytotoxicity).

Mechanistic studies
All experiments were performed after 24 hr incubation period for cell attachment. ROS
studies are performed using glass bottom 96-well plates, experiments for DNA DSB analysis are
plated on glass chamber slides for imaging and COMET assay studies are plated normally and
transferred to provided slide Cells are also treated for 24 hrs according to assigned treatment
group prior to RT. ROS production was evaluated using the ROS-Glo kit (G8820, Promega). DSB
was evaluated by fixing cells and exposing them to anti-g-H2AX (Abcam ab11174) or anti-53BP1
(Abcam ab172580) primary antibodies after blocking with 5% BSA.overnight at 4°C. They were
then stained with secondary antibodies conjugated to Alexa Fluor 647 (Texas Red –
ThermoFisher Scientific A32723) or Alexa Fluor 488 (FITC – ThermoFisher Scientific A31852)
for 2 hours at room temperature, and lastly stained with DAPI (blue). Images were captured using
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a fluorescence microscope (Leica DMI6000B, Leica Microsystems, Wetzlar, Germany) and foci
of immunofluorescence within the nuclei were analyzed using SPOT software (Sterling Heights,
MI, USA). At least 50 nuclei were counted per experimental condition. Seahorse analysis was
performed per Agilent specifications for the assay (manual part number 103016-400 and kit part
number 103015-100). The TMRE transmitochondiral membrane potential assay was evaluated
using the Abcam kit instructions (Ab113852).

In vivo studies
All animal studies were performed in accordance with IACUC guidelines with the approval
of the MD Anderson/UTHealth animal facility committee. Six to eight-week-old male nude mice
(Swiss nu/nu) were obtained from our animal facility and housed with a 12-hour light/dark cycle
at 22℃, with food and water ad libitum. Human pancreatic Panc-1 or Mia-Paca xenografts were
grown in the hind upper right leg of mice by injecting 0.5 – 1x106 cultured cells subcutaneously
while mice were under Ketamine and Xylazine anesthesia. Tumors were grown to 6 – 7 mm
diameter size prior to any treatment.

Biodistribution studies
For all biodistribution experiments, a delay of 24 hours was carried out between
nanoparticle treatment and organ collection. Following tissue collection, samples were stored in
pre-weighed glass vials and frozen at -80℃ until further processing. Frozen samples were
lyophilized for 2 – 7 days to ensure complete dehydration of tissues, then dry weights of tissues
acquired. Afterwards, 1 mL of Aqua Regia was added to each vial for digestion of tissues with
slight heating for more dense tissues like liver and brain. 1% nitric acid solution was added to
digested samples to bring the final volume to 10 mL for each sample, and this solution filtered
through a 0.25 µm microfilters prior to inductively coupled mass spectrometry (ICP-MS) analysis.
Liver and spleen samples were further diluted based on previous experimental data generated
in the lab.
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Tumor growth delay studies
Xenograft pancreatic tumors were used to assess tumor growth delay. Mice receiving
combined AuNS and radiation (RT) were injected with 100 µL of 20 OD of either pAuNS, sAuNS
or nAuNS 24 hours prior to RT. Control mice treated using only RT received 100 µL PBS. Mice
were anesthetized with 100 – 200 µL of 5% Ketamine and 10% Xylazine in PBS by intraperitoneal
injection ~20 minutes prior to irradiation. RT was delivered using a Philips RT-250 orthovoltage
unit equipped with a cone applicator to focus radiation toward the tumor target. The settings for
RT delivery included a 250 kVp beam with a Cu-filter, and an experimentally measured cone
application factor to properly correct the dose rate determined under standard conditions.

Tumors were measured in millimeters using calipers along the long (L) and short (S) axes
one day prior to and the day of RT, then 2 – 3 times weekly post-RT treatment. Tumor volumes
are calculated using the equation below. Tumor volumes were normalized to the starting tumor
volume for each mouse.

Liposomal and hyperthermia studies
Hyperthermia treatments were delivered using a water bath with a temperature set to
44℃ in order to maintain a temperature of 42℃ at the surface. Mice were anesthetized with 100
– 200 µL of 5% Ketamine and 10% Xylazine in PBS by intraperitoneal injection, and suspended
in Styrofoam floaters with a cut-out to allow extension of the hind limb bearing the implanted
tumors into the water bath. Tumors were exposed for 5 min, and mice transferred to a warming
blanket to sleep off the anesthesia. For the biodistribution and tumor growth delay with
hyperthermia experiments, a delay of 24 hours was completed between liposome treatment, then
again after liposome treatment prior to organ harvest or RT for a total of 48 hours from
nanoparticle-liposome injection.
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Measurement of complement activation in vitro
Nanoparticles were incubated with undiluted normal human serum collected and isolated
from 5 healthy individuals at 37 C for 30min. Activation of the classical, metabolic and lechitin
complement pathways was determined by using a kit (WIESLAB® Complement system Screen).
In a typical experiment, 10uL of nanoparticle formulation was mixed with 50 uL serum in
Eppendorf tubes then incubated for 30min at 37 C. The serum was then diluted with reagents for
blank samples, positive and negative controls, and reagents for the respective pathways for 60
– 70 min at 37 C per the protocol. Subsequently, the samples were washed 3 times, incubated
with substrate solution provided for another 30 min prior to measurement of the absorbance with
a microplate reader at 405 nm.

Measurement of coagulation assays in vitro
Similar to the complement activation assay, GNPs were incubated with normal human
plasma in isolated from 4 healthy donors at 37 C for 30min. All samples were run in triplicate.
The samples were then immediately submitted to the Division of Laboratory Medicine core at MD
Anderson Cancer Center for evaluation of prothrombin time (PT), the International Normalized
Ratio (INR), activated partial thromboplastin time (aPTT) and thrombin time (TT).

Statistical analysis
Statistical analysis: Quantitative data are presented as mean + standard deviation, or
mean + standard error of the mean. The differences between groups were compared using a
student’s t-test or one-way analysis of variance (ANOVA) with repeated measures, then followed
by Tukey’s HSD test. Tumor volumes were compared using a Kruskal-Wallis test then a MannWhitney test. Aggregate survival in various groups were compared using Kaplan-Meier curves
and the Log-rank test. Two-sided p-values less than 0.01 were considered statistically significant.
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